{
    "title": "Endometrial biomarkers for the non\u2010invasive diagnosis of endometriosis",
    "abstract": "Background About 10% of reproductive\u2010aged women suffer from endometriosis, which is a costly, chronic disease that causes pelvic pain and subfertility. Laparoscopy is the gold standard diagnostic test for endometriosis, but it is expensive and carries surgical risks. Currently, there are no non\u2010invasive tests available in clinical practice that accurately diagnose endometriosis. This is the first diagnostic test accuracy review of endometrial biomarkers for endometriosis that utilises Cochrane methodologies, providing an update on the rapidly expanding literature in this field.    Objectives To determine the diagnostic accuracy of the endometrial biomarkers for pelvic endometriosis, using a surgical diagnosis as the reference standard. We evaluated the tests as replacement tests for diagnostic surgery and as triage tests to inform decisions to undertake surgery for endometriosis.    Search methods We did not restrict the searches to particular study designs, language or publication dates. To identify trials, we searched the following databases: CENTRAL (2015, July), MEDLINE (inception to May 2015), EMBASE (inception to May 2015), CINAHL (inception to April 2015), PsycINFO (inception to April 2015), Web of Science (inception to April 2015), LILACS (inception to April 2015), OAIster (inception to April 2015), TRIP (inception to April 2015) and ClinicalTrials.gov (inception to April 2015). We searched DARE and PubMed databases up to April 2015 to identify reviews and guidelines as sources of references to potentially relevant studies. We also performed searches for papers recently published and not yet indexed in the major databases. The search strategies incorporated words in the title, abstract, text words across the record and the medical subject headings (MeSH).    Selection criteria We considered published peer\u2010reviewed, randomised controlled or cross\u2010sectional studies of any size that included prospectively collected samples from any population of reproductive\u2010aged women suspected of having one or more of the following target conditions: ovarian, peritoneal or deep infiltrating endometriosis (DIE).    Data collection and analysis Two authors independently extracted data from each study and performed a quality assessment. For each endometrial diagnostic test, we classified the data as positive or negative for the surgical detection of endometriosis and calculated the estimates of sensitivity and specificity. We considered two or more tests evaluated in the same cohort as separate data sets. We used the bivariate model to obtain pooled estimates of sensitivity and specificity whenever sufficient data were available. The predetermined criteria for a clinically useful test to replace diagnostic surgery was one with a sensitivity of 94% and a specificity of 79%. The criteria for triage tests were set at sensitivity at or above 95% and specificity at or above 50%, which in case of negative results rules out the diagnosis (SnOUT test) or sensitivity at or above 50% with specificity at or above 95%, which in case of positive result rules in the diagnosis (SpIN test).    Main results We included 54 studies involving 2729 participants, most of which were of poor methodological quality. The studies evaluated endometrial biomarkers either in specific phases of the menstrual cycle or outside of it, and the studies tested the biomarkers either in menstrual fluid, in whole endometrial tissue or in separate endometrial components. Twenty\u2010seven studies evaluated the diagnostic performance of 22 endometrial biomarkers for endometriosis. These were angiogenesis and growth factors (PROK\u20101), cell\u2010adhesion molecules (integrins \u03b13\u03b21, \u03b14\u03b21, \u03b21 and \u03b16), DNA\u2010repair molecules (hTERT), endometrial and mitochondrial proteome, hormonal markers (CYP19, 17\u03b2HSD2, ER\u2010\u03b1, ER\u2010\u03b2), inflammatory markers (IL\u20101R2), myogenic markers (caldesmon, CALD\u20101), neural markers (PGP 9.5, VIP, CGRP, SP, NPY, NF) and tumour markers (CA\u2010125). Most of these biomarkers were assessed in single studies, whilst only data for PGP 9.5 and CYP19 were available for meta\u2010analysis. These two biomarkers demonstrated significant diversity for the diagnostic estimates between the studies; however, the data were too limited to reliably determine the sources of heterogeneity. The mean sensitivities and specificities of PGP 9.5 (7 studies, 361 women) were 0.96 (95% confidence interval (CI) 0.91 to 1.00) and 0.86 (95% CI 0.70 to 1.00), after excluding one outlier study, and for CYP19 (8 studies, 444 women), they were were 0.77 (95% CI 0.70 to 0.85) and 0.74 (95% CI 0.65 to 84), respectively. We could not statistically evaluate other biomarkers in a meaningful way. An additional 31 studies evaluated 77 biomarkers that showed no evidence of differences in expression levels between the groups of women with and without endometriosis.    Authors' conclusions We could not statistically evaluate most of the biomarkers assessed in this review in a meaningful way. In view of the low quality of most of the included studies, the findings of this review should be interpreted with caution. Although PGP 9.5 met the criteria for a replacement test, it demonstrated considerable inter study heterogeneity in diagnostic estimates, the source of which could not be determined. Several endometrial biomarkers, such as endometrial proteome, 17\u03b2HSD2, IL\u20101R2, caldesmon and other neural markers (VIP, CGRP, SP, NPY and combination of VIP, PGP 9.5 and SP) showed promising evidence of diagnostic accuracy, but there was insufficient or poor quality evidence for any clinical recommendations. Laparoscopy remains the gold standard for the diagnosis of endometriosis, and using any non\u2010invasive tests should only be undertaken in a research setting. We have also identified a number of biomarkers that demonstrated no diagnostic value for endometriosis. We recommend that researchers direct future studies towards biomarkers with high diagnostic potential in good quality diagnostic studies.",
    "review_type": "Diagnostic",
    "doi": "https://doi.org/10.1002/14651858.CD012165",
    "review_id": "CD012165",
    "criteria": {
        "Types of studies": "Published peer\u2010reviewed studies that compared the results of one or several types of eutopic endometrial biomarker tests with the results obtained by surgical visualisation of lesions for the diagnosis of endometriosis. We included the following types of studies. Randomised controlled trials.   Observational studies with the following designs.   'Single\u2010gate design' (studies with a single set of inclusion criteria defined by clinical presentation). All participants had clinically suspected endometriosis.    'Two\u2010gate design' (studies where participants are sampled from distinct populations with respect to clinical presentation). The same study includes participants with a clinical suspicion of having the target condition (e.g. women with pelvic pain) and also participants in whom the target condition is not suspected (e.g. women admitted for tubal ligation). Two\u2010gate studies were eligible only where all cases and controls belonged to the same population with respect to the reference standard (i.e. all the participants were scheduled for laparoscopy) (Rutjes 2005).      Studies performed on prospectively collected samples, irrespective of the actual time of the test assay. The timing of sample collection relative to surgery is important because the surgical excision of endometriotic lesions could influence endometrial biomarker expression and hence bias the results. Therefore, we only included studies where the biological sample was collected before the surgical procedure, i.e. 'prospectively collected'. We considered to be eligible the studies performed on tissue bank samples collected from prospectively recruited, well\u2010defined populations, which prevented the omission of valuable data from adequately designed studies. The time interval between sample collection and laboratory testing may influence test outcomes, which could be dependent on sample storage conditions and the stability of each individual biomarker during storage and freeze\u2010thawing. This information was not readily available for most molecules, and we did not address it in this review, but we will consider it in future updates if more evidence emerges. Randomised controlled trials. Observational studies with the following designs. 'Single\u2010gate design' (studies with a single set of inclusion criteria defined by clinical presentation). All participants had clinically suspected endometriosis. 'Two\u2010gate design' (studies where participants are sampled from distinct populations with respect to clinical presentation). The same study includes participants with a clinical suspicion of having the target condition (e.g. women with pelvic pain) and also participants in whom the target condition is not suspected (e.g. women admitted for tubal ligation). Two\u2010gate studies were eligible only where all cases and controls belonged to the same population with respect to the reference standard (i.e. all the participants were scheduled for laparoscopy) (Rutjes 2005). Studies performed on prospectively collected samples, irrespective of the actual time of the test assay. The timing of sample collection relative to surgery is important because the surgical excision of endometriotic lesions could influence endometrial biomarker expression and hence bias the results. Therefore, we only included studies where the biological sample was collected before the surgical procedure, i.e. 'prospectively collected'. We considered to be eligible the studies performed on tissue bank samples collected from prospectively recruited, well\u2010defined populations, which prevented the omission of valuable data from adequately designed studies. The time interval between sample collection and laboratory testing may influence test outcomes, which could be dependent on sample storage conditions and the stability of each individual biomarker during storage and freeze\u2010thawing. This information was not readily available for most molecules, and we did not address it in this review, but we will consider it in future updates if more evidence emerges. We did not impose limits on eligibility related to the healthcare settings where the study took place, the language of publication, the number of participants in the included studies or the number of studies that evaluated each index test. We excluded the following types of studies. Narrative or systematic reviews.   Studies of retrospective design where investigators collected samples after execution of the reference test.    Studies of retrospective design where investigators selected participants from retrospective review of the case notes/archived samples and where information on recruitment methods or study population was not available.    Case reports or case series.   Studies reported only in abstract form or in conference proceedings where the full text was not available. We applied this limitation after facing substantial difficulty in obtaining the information from the abstracts, which precluded a reliable assessment of eligibility and methodological quality. Narrative or systematic reviews. Studies of retrospective design where investigators collected samples after execution of the reference test. Studies of retrospective design where investigators selected participants from retrospective review of the case notes/archived samples and where information on recruitment methods or study population was not available. Case reports or case series. Studies reported only in abstract form or in conference proceedings where the full text was not available. We applied this limitation after facing substantial difficulty in obtaining the information from the abstracts, which precluded a reliable assessment of eligibility and methodological quality.",
        "Participants": "Study participants included reproductive\u2010aged women (puberty to menopause) with suspected endometriosis based on clinical symptoms, pelvic examination or both, who undertook the index test as well as the reference standard. Participants came from populations of women undergoing abdominal surgery for the following indications. Clinically suspected endometriosis (pelvic pain, infertility, abnormal pelvic examination, or a combination of the above).    Ovarian mass, regardless of symptoms.   A mixed group consisting of women with suspected endometriosis/ovarian mass or women with other benign gynaecological conditions (e.g. surgical sterilisation, fibroid uterus, etc).    Asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication. Clinically suspected endometriosis (pelvic pain, infertility, abnormal pelvic examination, or a combination of the above). Ovarian mass, regardless of symptoms. A mixed group consisting of women with suspected endometriosis/ovarian mass or women with other benign gynaecological conditions (e.g. surgical sterilisation, fibroid uterus, etc). Asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication. Articles that included participants of postmenopausal age were eligible when the data for the reproductive age group was available in isolation. We excluded studies with participants that clearly would not undergo the index test in the relevant clinical situation or would not benefit from the test (e.g. women with ectopic pregnancies or acute pelvic inflammatory disease). We also excluded publications that only analysed participants with a positive index test or reference standard and did not provide data for the whole cohort.",
        "Index tests": "Any type of eutopic endometrial biomarker (including biomarkers in menstrual fluid), which were assessed either separately or in combination with other endometrial tests. We have classified the assessed index tests according to the type of biomarker, presented these categories in Table 3. To assist readers in the search for a specific biomarker, we include an index of all biomarkers with biological annotation in Appendix 1. Biomarker Diagnostic potential for endometriosis 1 Angiogenesis and growth factors and their receptors A EGF (epidermal growth factor) Expression not altered in endometriosis B FGF\u20102 (fibroblast growth factor\u20102) Expression not altered in endometriosis C Glycodelin A (PP14 or PAEP) (placental protein 14 or progestogen\u2010associated endometrial protein) Expression not altered in endometriosis D PDGF (platelet derived growth factor) Expression not altered in endometriosis E PIGF (placental growth factor) Expression not altered in endometriosis F PKR1 (prokineticin receptor 1), EG\u2010VEGF receptor Expression not altered in endometriosis G PKR2 (prokineticin receptor 2), EG\u2010VEGF receptor Expression not altered in endometriosis H PROK\u20101 (prokineticin 1) Diagnostic accuracy assessed I TSP\u20101 (thrombospondin\u20101) Expression not altered in endometriosis J TYMP (thymidine phosphorylase) Expression not altered in endometriosis K VEGF (vascular endothelial growth factor) Expression not altered in endometriosis 2 Apoptosis markers and regulators A Bax (BCL2\u2010associated X protein) Expression not altered in endometriosis B Bcl\u2010xL (B\u2010cell lymphoma\u2010extra large, or BCL2\u2010like 1 isoform 1) Expression not altered in endometriosis C Bcl\u2010xL:Bcl\u2010xS ratio (ratio B\u2010cell lymphoma\u2010extra large/B\u2010cell lymphoma\u2010extra small) Expression not altered in endometriosis 3 Cell adhesion molecules and other matrix\u2010related proteins A \u03b12\u03b21 integrin Expression not altered in endometriosis B \u03b13\u03b21 integrin Diagnostic accuracy assessed; expression not altered in endometriosis in some studies C \u03b14\u03b21 integrin Diagnostic accuracy assessed; expression not altered in endometriosis in some studies D \u03b15\u03b21 integrin Expression not altered in endometriosis E \u03b16\u03b21 integrin Expression not altered in endometriosis F \u03b1V\u03b23 integrin Expression not altered in endometriosis G \u03b1V\u03b25 integrins Expression not altered in endometriosis H \u03b1V\u03b26 integrins Expression not altered in endometriosis I \u03b21 integrin Diagnostic accuracy assessed J Depolarised \u03b16 integrin Diagnostic accuracy assessed K ICAM\u20101 (intercellular adhesion molecule\u20101) or sICAM\u20101 (soluble form of intercellular adhesion molecule\u20101) Expression not altered in endometriosis L E\u2010cadherin Expression not altered in endometriosis M LAMA5 (laminin subunit alpha\u20105) Expression not altered in endometriosis N LFA\u20103 (CD58) (leukocyte function associated molecule\u20103) Expression not altered in endometriosis O MMP\u20101 (matrix metalloproteinase\u20101) Expression not altered in endometriosis P MMP\u20109 (matrix metalloproteinase\u20109) Expression not altered in endometriosis Q OPN (osteopontin) Expression not altered in endometriosis R PAI\u20101/\u20102/\u20103 (plasminogen activator inhibitors 1/2/3) Expression not altered in endometriosis S PAs: tPA, uPA (plasminogen activators: tissue\u2010type PA, urokinase\u2010type PA) Expression not altered in endometriosis T TIMP\u20101 (tissue inhibitor of metalloproteinases) Expression not altered in endometriosis U VCAM\u20101 (CD106) (vascular cell adhesion molecule\u20101) Expression not altered in endometriosis 4 Cell cycle regulatory molecules A Cyclin B1 Expression not altered in endometriosis B Cdc2 (cyclin dependent kinase\u20102) Expression not altered in endometriosis 3 CPlk1 (polo\u2010like kinase\u20101) Expression not altered in endometriosis 5 Cell proliferation markers A Ki\u201067 (antigen KI\u201067 or MKI67, marker of cellular proliferation) Expression not altered in endometriosis B BW 495/36, endometrial epithelial marker Expression not altered in endometriosis 6 Cytoskeleton molecules A Cytokeratin 18 Expression not altered in endometriosis B CK19 or CYFRA 21\u20101 (cytokeratin 19) Expression not altered in endometriosis C Vimentin Expression not altered in endometriosis 7 DNA\u2010repair and telomer maintenance molecules A hTERT (human telomerase reverse transcriptase) Diagnostic accuracy assessed B Telomerase activity Expression not altered in endometriosis 8 High throughput markers A Endometrial proteome Diagnostic accuracy assessed B Mitochondrial proteome Diagnostic accuracy assessed C mRNAome (mRNA micro\u2010array) Expression not altered in endometriosis 9 Hormonal markers A 17\u03b2HSD2 (17\u2010\u03b2 hydroxysteroid dehydrogenase type 2) Diagnostic accuracy assessed B CYP19 (aromatase cytochrome P450) Diagnostic accuracy assessed C ER\u2010\u03b1 (oestrogen receptor\u2010alpha) Diagnostic accuracy assessed D ER\u2010\u03b2 (oestrogen receptor\u2010beta) Diagnostic accuracy assessed E EST (oestrogen sulphotransferase) Expression not altered in endometriosis F LGR7 (leucine\u2010rich G protein\u2010coupled receptor 7), relaxin receptor Expression not altered in endometriosis G Relaxin Expression not altered in endometriosis 10 Immune system and inflammatory markers A Cytokines i LIF (leukaemia\u2010inhibitory factor) Expression not altered in endometriosis ii TNF\u2010\u03b1 (tumour necrosis factor alpha) Expression not altered in endometriosis B Immune cells: peripheral blood mononuclear cells (PBMC) i Lymphocytes Expression not altered in endometriosis ii B\u2010lymphocytes Expression not altered in endometriosis iii Monocytes/macrophages Expression not altered in endometriosis iv NK (natural killer cells) Expression not altered in endometriosis v T\u2010lymphocytes Expression not altered in endometriosis C Interleukins i IL\u20101\u03b2 Expression not altered in endometriosis ii IL\u201011 Expression not altered in endometriosis iii IL\u20101R1 (interleukin\u20101 receptor type II) Expression not altered in endometriosis iv IL\u20101R2 (interleukin\u20101 receptor type II) Diagnostic accuracy assessed D Other immune/inflammatory markers i MPO (myeloperoxidase) Expression not altered in endometriosis ii NAG (N\u2010acetyl\u2010b\u2010D\u2010Glucosaminidase) Expression not altered in endometriosis 11 Mediators of prostaglandin biosynthesis A Akr1B1 mRNA (aldoketoreductase \u20101B1, PGF2a synthase) Expression not altered in endometriosis B Akr1C3 mRNA (aldoketoreductase \u20101C3, PGF2a synthase) Expression not altered in endometriosis C Cox\u20101 mRNA (cyclo\u2010oxygenase\u20101) Expression not altered in endometriosis D 15\u2010PGDH mRNA (15\u2010hydroxyprostaglandin dehydrogenase) Expression not altered in endometriosis E cPGES mRNA (cytosolic PGE2 synthase) Expression not altered in endometriosis 12 Myogenic markers (markers of smooth muscle differentiation) A Caldesmon (calmodulin binding protein) Diagnostic accuracy assessed B CALD1 (gene encoding for caldesmon) Diagnostic accuracy assessed 13 Nerve sheath and nerve growth markers A CGRP (calcitonin gene\u2010related protein) Diagnostic accuracy assessed B NF (neurofilament) Diagnostic accuracy assessed, but expression not altered in endometriosis C NPY (neuropeptide Y) Diagnostic accuracy assessed D PGP 9.5 (protein gene product 9.5) Diagnostic accuracy assessed, expression not altered in endometriosis in some studies E SP (substance P) Diagnostic accuracy assessed F VIP (vasoactive intestinal polypeptide) Diagnostic accuracy assessed 14 Other peptides and proteins A hBD\u20102 (human b\u2010defensin\u20102) Expression not altered in endometriosis 15 Transcription factors and signalling molecules A AKT1 (RAC\u2010alpha serine/threonine\u2010protein kinase) Expression not altered in endometriosis B JAG1 (jagged\u20101 protein) Expression not altered in endometriosis 16 Tumour markers A CA\u2010125 (cancer antigen 125) in menstrual fluid Diagnostic accuracy assessed We included index tests performed on the whole tissue sample or separate endometrial compartments and reported them the same way as presented by the authors (e.g. separate testing of glandular epithelium, stromal cells or mixed cell sample). We included tests performed in one or several phases of the menstrual cycle. The combined evaluations of endometrial biomarkers with other methods for diagnosing endometriosis (e.g. pelvic examination or blood tests) are beyond the scope of this review and are presented separately in another review: 'Combined tests for the non\u2010invasive diagnosis of endometriosis'. We excluded the studies that solely assessed specific technical aspects, qualitative descriptions of lesion appearance or interobserver variability of the index tests without reporting the data on diagnostic performance. We only considered studies in which the evaluated biomarker(s) showed differential expression between the groups of women with and without endometriosis if the data were reported in sufficient detail for the construction of 2 \u00d7 2 contingency tables. We included studies in which the expression levels of the index test did not significantly differ between the groups and where contingency tables were not available, as long as the inclusion criteria were met otherwise. We considered these to be studies reporting unchanged biomarker expression in the presence of endometriosis, and we presented them in the descriptive portion of the review. Thus, we evaluated the adequately designed studies that identified biomarkers without diagnostic value, as they provide information that is likely to guide future research towards other more clinically useful biomarkers. This methodology also identified biomarkers that presented conflicting findings associated with endometriosis in some but not other publications. We considered the diagnostic performance of an index test to be high when the test reached the criteria for a replacement test (sensitivity at or above 94% with specificity at or above 79%) or triage test (sensitivity at or above 95% with specificity at or above 50% or vice versa), or approached these criteria (diagnostic estimates within 5% of the set thresholds). We considered all other diagnostic estimates to be low.",
        "Target conditions": "Pelvic endometriosis, defined as endometrial tissue located in the pelvic cavity: involving any of the pelvic organs, peritoneum and pouch of Douglas. We assessed three types of pelvic endometriosis. Peritoneal endometriosis, defined as endometrial deposits detected on peritoneum covering pelvic organs, pelvic side walls or pouch of Douglas.    Ovarian endometriosis (endometrioma), defined as an ovarian cyst lined by endometrial tissue, appearing as an ovarian mass of varying size.    Deep infiltrating endometriosis (DIE), defined as subperitoneal infiltration of endometrial implants, i.e. when the endometriotic implants penetrate the retroperitoneal space at a distance of 5 mm or more (Koninckx 1991). DIE may be present in multiple locations, involving either the anterior or posterior pelvic compartments, or both. Peritoneal endometriosis, defined as endometrial deposits detected on peritoneum covering pelvic organs, pelvic side walls or pouch of Douglas. Ovarian endometriosis (endometrioma), defined as an ovarian cyst lined by endometrial tissue, appearing as an ovarian mass of varying size. Deep infiltrating endometriosis (DIE), defined as subperitoneal infiltration of endometrial implants, i.e. when the endometriotic implants penetrate the retroperitoneal space at a distance of 5 mm or more (Koninckx 1991). DIE may be present in multiple locations, involving either the anterior or posterior pelvic compartments, or both. We did not include certain rare types of endometriosis such as extrapelvic, bladder and ureteric endometriosis because the majority were reported in case reports or case series, and laparoscopy or laparotomy are not reliable reference standards for these conditions. We excluded the studies where diagnosis of endometriosis was not the primary outcome (e.g. malignant versus benign masses or normal versus abnormal pelvis) and separate data for endometriosis was not available. We did include studies that recruited selected populations of women with endometriosis (i.e. those with specific rASRM stages), because there is a poor correlation between the rASRM classification and infertility or pain symptoms. Exclusion of these studies could result in the loss of potentially important diagnostic information from otherwise eligible publications. Where possible, we addressed the impact of these studies in the assessment of heterogeneity. When a study analysed a large population with a wide spectrum of endometriosis and additionally reported a subgroup analysis of the different stages of disease severity, we only considered estimates for the entire population. This is because a subgroup analysis would not directly address the review question regarding the clinical utility of the biomarker in disease detection.",
        "Reference standards": "The reference standard was visualisation of endometriosis at surgery (laparoscopy or laparotomy) with or without histological confirmation, as this is currently the best available test for endometriosis. If reported, we reviewed information regarding the inter\u2010 and intraobserver correlation of the reference standard. We only included studies in which the reference test was performed within 12 months of the sample collection, on the assumption that disease status could change within a period of one year or longer, either naturally or as a result of treatment. We excluded studies in which the participants did not undergo the reference standard or where the findings of the index test formed the basis of selection for undertaking the reference standard, as this was likely to distort an assessment of the diagnostic value of the index test. Types of studies   Published and peer\u2010reviewed   RCTs   Observational designs, including:   single\u2010gate design (single set of inclusion criteria defined by clinical presentation): all the participants had clinically suspected endometriosis;    two\u2010gate design (two sets of inclusion criteria with respect to clinical presentation and one set of inclusion criteria with respect to reference standard): the participants with or without a clinical suspicion of endometriosis scheduled for abdominal surgery;      Published in any language   Performed in any healthcare setting   Any sample size   Prospectively recruited participants (consecutive or non\u2010consecutive enrolment)     Participants   Reproductive\u2010aged women   Clinically suspected endometriosis, including:   women who underwent abdominal surgery for other benign gynaecological conditions and had a surgical assessment for presence/absence of endometriosis;    asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication;      Undertook both the index test and reference standard     Index tests   One or several types of eutopic endometrial biomarkers (including biomarkers in menstrual fluid)    Data reported in sufficient detail for the construction of 2 \u00d7 2 tables for the tests that showed differential expression between the groups      Target condition   Pelvic endometriosis: peritoneal endometriosis, ovarian endometrioma, DIE or combinations of the above      Reference standard   Surgical visualisation of lesions for the diagnosis of endometriosis (laparoscopy or laparotomy) with or without histological verification    Performed within 12 months of the endometrial sample collection Types of studies Published and peer\u2010reviewed RCTs Observational designs, including: single\u2010gate design (single set of inclusion criteria defined by clinical presentation): all the participants had clinically suspected endometriosis; two\u2010gate design (two sets of inclusion criteria with respect to clinical presentation and one set of inclusion criteria with respect to reference standard): the participants with or without a clinical suspicion of endometriosis scheduled for abdominal surgery; Published in any language Performed in any healthcare setting Any sample size Prospectively recruited participants (consecutive or non\u2010consecutive enrolment) Participants Reproductive\u2010aged women Clinically suspected endometriosis, including: women who underwent abdominal surgery for other benign gynaecological conditions and had a surgical assessment for presence/absence of endometriosis; asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication; Undertook both the index test and reference standard Index tests One or several types of eutopic endometrial biomarkers (including biomarkers in menstrual fluid) Data reported in sufficient detail for the construction of 2 \u00d7 2 tables for the tests that showed differential expression between the groups Target condition Pelvic endometriosis: peritoneal endometriosis, ovarian endometrioma, DIE or combinations of the above Reference standard Surgical visualisation of lesions for the diagnosis of endometriosis (laparoscopy or laparotomy) with or without histological verification Performed within 12 months of the endometrial sample collection Types of studies   Narrative or systematic reviews   Retrospective design where the index test was performed after execution of reference test or participants were selected from retrospective review of the case notes    Prospectively collected samples that were selected from the archived material, but where information on the study population or the selection process was unclear    Case reports or case series   Conference proceedings     Participants   Included cohort was not representative of the target population that would benefit from the test (e.g. women with known genital tract malignancy, ectopic pregnancies or acute pelvic inflammatory disease)    Study included participants of postmenopausal age, where data for the reproductive age group were not available in isolation    Only participants with positive index test or positive reference standard were included in the analysis;      Index tests   Endometrial biomarkers presented in combination with other diagnostic tests for endometriosis and where separate information for endometrial biomarkers was not available    Study presented only specific technical aspects of an index test or data on interobserver variability    Study presented only qualitative description of the tissue samples or focused on the biological events, rather than diagnostic performance of the test      Target condition   Endometriosis was not the primary outcome of the trial (e.g. malignant versus benign masses or normal versus abnormal pelvis)    Atypical, rare sites of endometriosis     Reference standard   Endometriosis was not the primary outcome of the trial (e.g. malignant versus benign masses or normal versus abnormal pelvis)    Reference standard performed only in a subset of the study or control group   Findings of the index test formed the basis of selection for the reference standard Types of studies Narrative or systematic reviews Retrospective design where the index test was performed after execution of reference test or participants were selected from retrospective review of the case notes Prospectively collected samples that were selected from the archived material, but where information on the study population or the selection process was unclear Case reports or case series Conference proceedings Participants Included cohort was not representative of the target population that would benefit from the test (e.g. women with known genital tract malignancy, ectopic pregnancies or acute pelvic inflammatory disease) Study included participants of postmenopausal age, where data for the reproductive age group were not available in isolation Only participants with positive index test or positive reference standard were included in the analysis; Index tests Endometrial biomarkers presented in combination with other diagnostic tests for endometriosis and where separate information for endometrial biomarkers was not available Study presented only specific technical aspects of an index test or data on interobserver variability Study presented only qualitative description of the tissue samples or focused on the biological events, rather than diagnostic performance of the test Target condition Endometriosis was not the primary outcome of the trial (e.g. malignant versus benign masses or normal versus abnormal pelvis) Atypical, rare sites of endometriosis Reference standard Endometriosis was not the primary outcome of the trial (e.g. malignant versus benign masses or normal versus abnormal pelvis) Reference standard performed only in a subset of the study or control group Findings of the index test formed the basis of selection for the reference standard",
        "Summary of inclusion and exclusion criteria": "Inclusion criteria    Types of studies   Published and peer\u2010reviewed   RCTs   Observational designs, including:   single\u2010gate design (single set of inclusion criteria defined by clinical presentation): all the participants had clinically suspected endometriosis;    two\u2010gate design (two sets of inclusion criteria with respect to clinical presentation and one set of inclusion criteria with respect to reference standard): the participants with or without a clinical suspicion of endometriosis scheduled for abdominal surgery;      Published in any language   Performed in any healthcare setting   Any sample size   Prospectively recruited participants (consecutive or non\u2010consecutive enrolment)     Participants   Reproductive\u2010aged women   Clinically suspected endometriosis, including:   women who underwent abdominal surgery for other benign gynaecological conditions and had a surgical assessment for presence/absence of endometriosis;    asymptomatic women who have an incidental finding of endometriosis at surgery performed for another indication;      Undertook both the index test and reference standard     Index tests   One or several types of eutopic endometrial biomarkers (including biomarkers in menstrual fluid)    Data reported in sufficient detail for the construction of 2 \u00d7 2 tables for the tests that showed differential expression between the groups      Target condition   Pelvic endometriosis: peritoneal endometriosis, ovarian endometrioma, DIE or combinations of the above      Reference standard   Surgical visualisation of lesions for the diagnosis of endometriosis (laparoscopy or laparotomy) with or without histological verification    Performed within 12 months of the endometrial sample collection        Exclusion criteria    Types of studies   Narrative or systematic reviews   Retrospective design where the index test was performed after execution of reference test or participants were selected from retrospective review of the case notes    Prospectively collected samples that were selected from the archived material, but where information on the study population or the selection process was unclear    Case reports or case series   Conference proceedings     Participants   Included cohort was not representative of the target population that would benefit from the test (e.g. women with known genital tract malignancy, ectopic pregnancies or acute pelvic inflammatory disease)    Study included participants of postmenopausal age, where data for the reproductive age group were not available in isolation    Only participants with positive index test or positive reference standard were included in the analysis;      Index tests   Endometrial biomarkers presented in combination with other diagnostic tests for endometriosis and where separate information for endometrial biomarkers was not available    Study presented only specific technical aspects of an index test or data on interobserver variability    Study presented only qualitative description of the tissue samples or focused on the biological events, rather than diagnostic performance of the test      Target condition   Endometriosis was not the primary outcome of the trial (e.g. malignant versus benign masses or normal versus abnormal pelvis)    Atypical, rare sites of endometriosis     Reference standard   Endometriosis was not the primary outcome of the trial (e.g. malignant versus benign masses or normal versus abnormal pelvis)    Reference standard performed only in a subset of the study or control group   Findings of the index test formed the basis of selection for the reference standard",
        "null": ""
    },
    "search_strategy": {
        "Appendix 1. Alphabetical index of endometrial biomarkers": "Biomarker    Biological group    Biological sub\u2010group      1   15\u2010PGDH mRNA (15\u2010hydroxyprostaglandin dehydrogenase)   Mediators of prostaglandin biosynthesis   \u2014     2   17\u03b2HSD2 (17\u2010\u03b2 hydroxysteroid dehydrogenase type 2)   Hormonal markers   \u2014     3   Akr1B1 mRNA (aldoketoreductase \u20101B1, PGF2a synthase)   Mediators of prostaglandin biosynthesis   \u2014     4   Akr1C3 mRNA (aldoketoreductase \u20101C3, PGF2a synthase)   Mediators of prostaglandin biosynthesis   \u2014     5   AKT1 (RAC\u2010alpha serine/threonine\u2010protein kinase)   Transcription factors and signalling molecules   \u2014     6   Bax (BCL2\u2010associated X protein)   Apoptosis markers and regulators   \u2014     7   Bcl\u2010xL (B\u2010cell lymphoma\u2010extra large, or BCL2\u2010like 1 isoform 1)   Apoptosis markers and regulators   \u2014     8   Bcl\u2010xL:Bcl\u2010xS ratio (ratio B\u2010cell lymphoma\u2010extra large/B\u2010cell lymphoma\u2010extra small)   Apoptosis markers and regulators   \u2014     9   BW 495/36, endometrial epithelial marker   Cell proliferation markers   \u2014     10   CD 4+ (T helper cells)   Immune system and inflammatory markers   Immune cells: peripheral blood mononuclear cells (PBMC)     11   CD 8+ (T suppressor cells)   Immune system and inflammatory markers   Immune cells: PBMC     12   CD 16+ (natural killer cells)   Immune system and inflammatory markers   Immune cells: PBMC     13   CD 22+ (B\u2010lymphocytes)   Immune system and inflammatory markers   Immune cells: PBMC     14   CD 38+ (granulated lymphocytes)   Immune system and inflammatory markers   Immune cells: PBMC     15   CD 56+ (granulated lymphocytes)   Immune system and inflammatory markers   Immune cells: PBMC     16   CD 68+ (macrophages)   Immune system and inflammatory markers   Immune cells: PBMC     17   CA\u2010125 (cancer antigen\u2010125) in menstrual fluid   Tumour markers   \u2014     18   CALD1 (gene encoding for caldesmon)   Myogenic markers   \u2014     19   Caldesmon (calmodulin binding protein)   Myogenic markers   \u2014     20   Cdc2 (cyclin dependent kinase\u20102)   Cell cycle regulatory molecules   \u2014     21   CGRP (calcitonin gene\u2010related protein)   Nerve sheath and nerve growth markers   \u2014     22   CK19 or CYFRA 21\u20101 (cytokeratin 19)   Cytoskeleton molecules   \u2014     23   Cox\u20101 mRNA (cyclo\u2010oxygenase\u20101)   Mediators of prostaglandin biosynthesis   \u2014     24   cPGES mRNA (cytosolic PGE2 synthase)   Mediators of prostaglandin biosynthesis   \u2014     25   Cyclin B1   Cell cycle regulatory molecules   \u2014     26   CYP19 (aromatase cytochrome P450)   Hormonal markers   \u2014     27   Cytokeratin 18   Cytoskeleton molecules      28   Depolarised \u03b16 Integrin   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     29   E\u2010cadherin   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     30   EGF (epidermal growth factor)   Angiogenesis and growth factors and their receptors   \u2014     31   Endometrial proteome   High throughput markers   \u2014     32   EST (oestrogen sulphotransferase)   Hormonal markers   \u2014     33   ER \u2010 \u03b1 (oestrogen receptor \u2010 alpha)    \u2014     34   ER \u2010 \u03b2 (oestrogen receptor \u2010 beta)    \u2014     35   FGF\u20102 (fibroblast growth factor\u20102)   Angiogenesis and growth factors and their receptors   \u2014     36   glycodelin A (PP14 or PAEP) ((placental protein 14 or progestogen\u2010associated endometrial protein))    Angiogenesis and growth factors and their receptors   \u2014     37   hBD\u20102 (human b\u2010defensin\u20102)   Other peptides and proteins   \u2014     38   hTERT (human telomerase reverse transcriptase)   DNA\u2010repair and Telomer maintenance molecules   \u2014     39   ICAM\u20101 (intercellular adhesion molecule\u20101) or sICAM\u20101 (soluble form of intercellular adhesion molecule\u20101)    Cell adhesion molecules and other matrix\u2010related proteins   \u2014     40   IL\u201011   Immune system and inflammatory markers   Interleukins     41   IL\u20101R1 (interleukin\u20101 receptor type II)   Immune system and inflammatory markers   Interleukins     42   IL\u20101R2 (interleukin\u20101 receptor type II)   Immune system and inflammatory markers   Interleukins     43   IL\u20101\u03b2   Immune system and inflammatory markers   Interleukins     44   JAG1 (jagged\u20101 protein)   Transcription factors and signalling molecules   \u2014     45   Ki\u201067 (antigen KI\u201067 or MKI67, marker of cellular proliferation)   Cell proliferation markers   \u2014     46   LAMA5 (laminin subunit alpha\u20105)   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     47   LFA\u20103 (CD58) (leukocyte function associated molecule\u20103)   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     48   LGR7 (leucine\u2010rich G protein\u2010coupled receptor 7), relaxin receptor   Hormonal markers   \u2014     49   LIF (leukaemia\u2010inhibitory factor)   Immune system and inflammatory markers   Cytokines     50   Mitochondrial proteome   High throughput markers   \u2014     51   MMP\u20101 (matrix metalloproteinase\u20101)   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     52   MMP\u20109 (matrix metalloproteinase\u20109)   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     53   MPO (myeloperoxidase)   Immune system and inflammatory markers   other immune/inflammatory markers     54   mRNAome (mRNA micro\u2010array)   High throughput markers   \u2014     55   NAG (N\u2010acetyl\u2010b\u2010D\u2010Glucosaminidase)   Immune system and inflammatory markers   other immune/inflammatory markers     56   NF (neurofilament)   Nerve sheath and nerve growth markers   \u2014     57   NPY (neuropeptide Y)   Nerve sheath and nerve growth markers   \u2014     58   OPN (osteopontin)   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     59\u201061   PAI\u20101/\u20102/\u20103 (plasminogen activator inhibitors 1/2/3)   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     62   PDGF (platelet derived growth factor)   Angiogenesis and growth factors and their receptors   \u2014     63   PGP 9.5 (protein gene product 9.5)   Nerve sheath and nerve growth markers   \u2014     64   PIGF (Placental growth factor)   Angiogenesis and growth factors and their receptors   \u2014     65   PKR1 (prokineticin receptor 1), EG\u2010VEGF receptor   Angiogenesis and growth factors and their receptors   \u2014     66   PKR2 (prokineticin receptor 2), EG\u2010VEGF receptor   Angiogenesis and growth factors and their receptors   \u2014     67   Plk1 (polo\u2010like kinase\u20101)   Cell cycle regulatory molecules   \u2014     68   PROK\u20101 (prokineticin 1)   Angiogenesis and growth factors and their receptors   \u2014     69   Relaxin   Hormonal markers   \u2014     70   SP (substance P)   Nerve sheath and nerve growth markers   \u2014     71   Telomerase activity   DNA\u2010repair and Telomer maintenance molecules   \u2014     72   TIMP\u20101 (tissue inhibitor of metalloproteinases)   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     73   TNF\u2010\u03b1 (tumour necrosis factor alpha)   Immune system and inflammatory markers   Cytokines     74   tPA (tissue\u2010type plasminogen activator)   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     75   TSP\u20101 (thrombospondin\u20101)   Angiogenesis and growth factors and their receptors   \u2014     76   TYMP (thymidine phosphorylase)   Angiogenesis and growth factors and their receptors   \u2014     77   uPA (urokinase\u2010type plasminogen activator)   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     78   VCAM\u20101 (CD106) (vascular cell adhesion molecule\u20101)   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     79   VEGF (vascular endothelial growth factor)   Angiogenesis and growth factors and their receptors   \u2014     80   Vimentin   Cytoskeleton molecules   \u2014     81   VIP (vasoactive intestinal polypeptide)   Nerve sheath and nerve growth markers   \u2014     82   \u03b12\u03b21 integrin   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     83   \u03b13\u03b21 integrin   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     84   \u03b14\u03b21 integrin   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     85   \u03b15\u03b21 integrin   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     86   \u03b16 \u03b21 integrin   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     87   \u03b1V\u03b23 integrin   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     88   \u03b1V\u03b25 integrins   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     89   \u03b1V\u03b26 integrins   Cell adhesion molecules and other matrix\u2010related proteins   \u2014     90   \u03b21 integrin   Cell adhesion molecules and other matrix\u2010related proteins   \u2014",
        "Appendix 2. Search strategy for CENTRAL (OVID platform)": "Database: EBM Reviews \u2010 Cochrane Central Register of Controlled Trials <July 2015 (3.09.2015)>  Search Strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 (biomarker$ or marker$).tw. (23692) 2 Laboratory Test$.tw. (2793) 3 growth factor$.tw. (5448) 4 scatter factor$.tw. (8) 5 cytokine$.tw. (6264) 6 hepatocyte growth factor.tw. (111) 7 (FGF or fibroblast growth factor$).tw. (433) 8 (PDGF or platelet derived growth factor$).tw. (250) 9 (EGF or epidermal growth factor$).tw. (1077) 10 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (2132) 11 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (519) 12 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (236) 13 (EGFR or epidermal growth factor receptor$).tw. (1905) 14 (VEGF or vascular endothelial growth factor$).tw. (1532) 15 exp Luteinizing Hormone/bl [Blood] (151) 16 leptin$.tw. (1399) 17 exp Progesterone/bl [Blood] (58) 18 Proteolytic enzyme$.tw. (136) 19 exp matrix metalloproteinase 1/ or exp matrix metalloproteinase 2/ or exp matrix metalloproteinase 3/ or exp matrix metalloproteinase 9/ (292)  20 matrix metalloproteinase$.tw. (676) 21 MMP$.tw. (905) 22 TIMP$.tw. (229) 23 exp \"tissue inhibitor of metalloproteinase\u20101\"/ or exp \"tissue inhibitor of metalloproteinase\u20102\"/ (101)  24 exp Glycoproteins/ (10108) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (305) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (71) 27 (PP 14 or PP14).tw. (23) 28 serum placental protein$.tw. (6) 29 exp Follistatin/ (13) 30 Osteopontin$.tw. (80) 31 exp intercellular adhesion molecule\u20101/ or exp selectins/ (929) 32 soluble intercellular adhesion.tw. (256) 33 Soluble adhesion molecule$.tw. (89) 34 sICAM.tw. (319) 35 sVCAM$.tw. (223) 36 (sEcadherin or soluble E\u2010cadherin).tw. (4) 37 (sEselectin or soluble E\u2010selectin).tw. (99) 38 exp t\u2010lymphocytes/ or exp natural killer t\u2010cells/ (2645) 39 Immune cells alteration$.tw. (1) 40 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (445) 41 Total complement level$.tw. (0) 42 Autoantibodies.tw. (428) 43 exp Antibodies, Antiphospholipid/ (85) 44 Anti\u2010endometrial.tw. (0) 45 Antiphospholipid$.tw. (152) 46 exp hla antigens/ or exp hla\u2010a1 antigen/ or exp hla\u2010a2 antigen/ (563) 47 (HLA or human leucocyte antigen$).tw. (1724) 48 Anti\u2010laminin\u20101.tw. (0) 49 Anti\u2010thyroid.tw. (49) 50 Anti\u2010Thomsen Friedenreich antigen$.tw. (0) 51 Anti\u2010transferrin.tw. (0) 52 Anti\u2010LDL.tw. (3) 53 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (0) 54 interleukin$.tw. (7276) 55 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (0) 56 (MIF or migration inhibitory factor$).tw. (75) 57 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (3923) 58 Fas ligand$.tw. (47) 59 Endometrial marker$.tw. (2) 60 CAMs.tw. (53) 61 cell adhesion molecule$.tw. (568) 62 exp Integrins/ (781) 63 Integrin$.tw. (248) 64 Selectin$.tw. (2183) 65 Cadherin$.tw. (71) 66 Aromatase P450.tw. (3) 67 estrogen receptor$.tw. (1252) 68 progesterone receptor$.tw. (531) 69 MTMMP$.tw. (0) 70 cyr61.tw. (1) 71 exp Cysteine\u2010Rich Protein 61/ (1) 72 cysteine\u2010rich heparin\u2010binding protein$.tw. (0) 73 (ANXA 1 or ANXA1).tw. (3) 74 (Annexin 1 or Annexin1).tw. (2) 75 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (18) 76 serum marker$.tw. (411) 77 neural marker$.tw. (9) 78 cell surface marker$.tw. (46) 79 inflammatory marker$.tw. (1739) 80 microarray$.tw. (501) 81 microRNA$.tw. (103) 82 proteomic$.tw. (176) 83 genomic$.tw. (526) 84 (endometri$ adj2 biops$).tw. (464) 85 Follistatin$.tw. (26) 86 Vascular Endothelial Growth Factor A/ (560) 87 Vitamin D\u2010Binding Protein/ (18) 88 exp Cytokines/ (13960) 89 exp interleukins/ or exp interleukin\u20101/ or exp interleukin\u20106/ or exp interleukin\u20108/ or exp interleukin\u201012/ or exp interleukin\u201013/ (4413)  90 exp Epidermal Growth Factor/ (91) 91 exp Fibroblast Growth Factors/ (197) 92 Platelet\u2010Derived Growth Factor/ (99) 93 Keratin\u201019/ (19) 94 exp Clinical Laboratory Techniques/ (35164) 95 (Luteinizing Hormone$ or LH).tw. (2935) 96 cytokeratin\u201019.tw. (25) 97 (VDBP or vitamin D\u2010binding protein$).tw. (44) 98 urinary peptide$.tw. (8) 99 VDBP\u2010Cr.tw. (0) 100 urinary VDBP corrected for creatinine expression.tw. (0) 101 urinary marker$.tw. (67) 102 or/1\u2010101 (90390) 103 Endometriosis/di [Diagnosis] (6) 104 102 or 103 (90394) 105 exp Endometriosis/ (469) 106 Endometrio$.tw. (1026) 107 105 or 106 (1067) 108 104 and 107 (226) 109 (animals not (humans and animals)).sh. (1) 110 108 not 109 (226)",
        "Appendix 3. Search strategy for MEDLINE (OVID platform)": "Database: MEDLINE (Ovid) <1946 to February, week 2 2015 (16.2.2015)> > Ovid MEDLINE(R) In\u2010Process & Other Non\u2010Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)  Search Strategy: 1 (biomarker$ or marker$).tw. (605002) 2 Laboratory Test$.tw. (29839) 3 growth factor$.tw. (272049) 4 scatter factor$.tw. (1287) 5 cytokine$.tw. (250618) 6 hepatocyte growth factor.tw. (8053) 7 (FGF or fibroblast growth factor$).tw. (31798) 8 (PDGF or platelet derived growth factor$).tw. (19864) 9 (EGF or epidermal growth factor$).tw. (58069) 10 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (43539) 11 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (281) 12 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (28842) 13 (EGFR or epidermal growth factor receptor$).tw. (41719) 14 (VEGF or vascular endothelial growth factor$).tw. (53588) 15 exp Luteinizing Hormone/bl (Blood) (24587) 16 leptin$.tw. (24994) 17 exp Progesterone/bl (Blood) (18412) 18 Proteolytic enzyme$.tw. (9768) 19 exp matrix metalloproteinase 1/ or exp matrix metalloproteinase 2/ or exp matrix metalloproteinase 3/ or exp matrix metalloproteinase 9/ (22968)  20 matrix metalloproteinase$.tw. (34522) 21 MMP$.tw. (44439) 22 TIMP$.tw. (10777) 23 exp \"tissue inhibitor of metalloproteinase\u20101\"/ or exp \"tissue inhibitor of metalloproteinase\u20102\"/ (6146)  24 exp Glycoproteins/ (637149) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (6761) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (4194) 27 (PP 14 or PP14).tw. (229) 28 serum placental protein$.tw. (33) 29 exp Follistatin/ (1134) 30 Osteopontin$.tw. (6769) 31 exp intercellular adhesion molecule\u20101/ or exp selectins/ (25302) 32 soluble intercellular adhesion.tw. (1588) 33 Soluble adhesion molecule$.tw. (779) 34 sICAM.tw. (2258) 35 sVCAM$.tw. (1277) 36 (sEcadherin or soluble E\u2010cadherin).tw. (95) 37 (sEselectin or soluble E\u2010selectin).tw. (689) 38 exp t\u2010lymphocytes/ or exp natural killer t\u2010cells/ (272580) 39 Immune cells alteration$.tw. (1) 40 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (21275) 41 Total complement level$.tw. (23) 42 Autoantibodies.tw. (33457) 43 exp Antibodies, Antiphospholipid/ (7522) 44 Anti\u2010endometrial.tw. (23) 45 Antiphospholipid$.tw. (9974) 46 exp hla antigens/ or exp hla\u2010a1 antigen/ or exp hla\u2010a2 antigen/ (64462) 47 (HLA or human leucocyte antigen$).tw. (80501) 48 Anti\u2010laminin\u20101.tw. (33) 49 Anti\u2010thyroid.tw. (1414) 50 Anti\u2010Thomsen Friedenreich antigen$.tw. (6) 51 Anti\u2010transferrin.tw. (275) 52 Anti\u2010LDL.tw. (181) 53 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (3) 54 interleukin$.tw. (175195) 55 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (44) 56 (MIF or migration inhibitory factor$).tw. (4479) 57 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (1344) 58 Fas ligand$.tw. (6032) 59 Endometrial marker$.tw. (11) 60 CAMs.tw. (1756) 61 cell adhesion molecule$.tw. (20903) 62 exp Integrins/ (44414) 63 Integrin$.tw. (39960) 64 Selectin$.tw. (55426) 65 Cadherin$.tw. (20780) 66 Aromatase P450.tw. (180) 67 estrogen receptor$.tw. (38819) 68 progesterone receptor$.tw. (16623) 69 MTMMP$.tw. (7) 70 cyr61.tw. (559) 71 exp Cysteine\u2010Rich Protein 61/ (386) 72 cysteine\u2010rich heparin\u2010binding protein$.tw. (9) 73 (ANXA 1 or ANXA1).tw. (313) 74 (Annexin 1 or Annexin1).tw. (339) 75 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2096) 76 serum marker$.tw. (5429) 77 neural marker$.tw. (925) 78 cell surface marker$.tw. (4456) 79 inflammatory marker$.tw. (10916) 80 microarray$.tw. (75404) 81 microRNA$.tw. (29731) 82 proteomic$.tw. (45292) 83 genomic$.tw. (190985) 84 (endometri$ adj2 biops$).tw. (3411) 85 Follistatin$.tw. (1663) 86 Vascular Endothelial Growth Factor A/ (35738) 87 Vitamin D\u2010Binding Protein/ (1282) 88 exp Cytokines/ (547522) 89 exp interleukins/ or exp interleukin\u20101/ or exp interleukin\u20106/ or exp interleukin\u20108/ or exp interleukin\u201012/ or exp interleukin\u201013/ (188479)  90 exp Epidermal Growth Factor/ (21298) 91 exp Fibroblast Growth Factors/ (25075) 92 Platelet\u2010Derived Growth Factor/ (11030) 93 Keratin\u201019/ (1090) 94 exp Clinical Laboratory Techniques/ (2132820) 95 (Luteinizing Hormone$ or LH).tw. (56679) 96 cytokeratin\u201019.tw. (1469) 97 (VDBP or vitamin D\u2010binding protein$).tw. (1158) 98 urinary peptide$.tw. (137) 99 VDBP\u2010Cr.tw. (1) 100 urinary VDBP corrected for creatinine expression.tw. (1) 101 urinary marker$.tw. (638) 102 or/1\u2010101 (4086291) 103 Endometriosis/di (Diagnosis) (3354) 104 102 or 103 (4088946) 105 exp Endometriosis/ (17244) 106 Endometrio$.tw. (21492) 107 105 or 106 (24940) 108 104 and 107 (10490) 109 (animals not (humans and animals)).sh. (3892900) 110 108 not 109 (10113) Additional search February 2015 \u2010 May 2015  Ovid MEDLINE(R) In\u2010Process & Other Non\u2010Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present (3.9.2015)>  Search Strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 (biomarker$ or marker$).tw. (652345) 2 Laboratory Test$.tw. (31389) 3 growth factor$.tw. (287701) 4 scatter factor$.tw. (1326) 5 cytokine$.tw. (267766) 6 hepatocyte growth factor.tw. (8585) 7 (FGF or fibroblast growth factor$).tw. (33674) 8 (PDGF or platelet derived growth factor$).tw. (20842) 9 (EGF or epidermal growth factor$).tw. (61625) 10 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (45386) 11 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (306) 12 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (30559) 13 (EGFR or epidermal growth factor receptor$).tw. (46446) 14 (VEGF or vascular endothelial growth factor$).tw. (58203) 15 exp Luteinizing Hormone/bl [Blood] (24870) 16 leptin$.tw. (26783) 17 exp Progesterone/bl [Blood] (18699) 18 Proteolytic enzyme$.tw. (9992) 19 exp matrix metalloproteinase 1/ or exp matrix metalloproteinase 2/ or exp matrix metalloproteinase 3/ or exp matrix metalloproteinase 9/ (24504)  20 matrix metalloproteinase$.tw. (37055) 21 MMP$.tw. (47849) 22 TIMP$.tw. (11419) 23 exp \"tissue inhibitor of metalloproteinase\u20101\"/ or exp \"tissue inhibitor of metalloproteinase\u20102\"/ (6447)  24 exp Glycoproteins/ (662211) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (7058) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (4399) 27 (PP 14 or PP14).tw. (232) 28 serum placental protein$.tw. (34) 29 exp Follistatin/ (1180) 30 Osteopontin$.tw. (7267) 31 exp intercellular adhesion molecule\u20101/ or exp selectins/ (26225) 32 soluble intercellular adhesion.tw. (1663) 33 Soluble adhesion molecule$.tw. (795) 34 sICAM.tw. (2374) 35 sVCAM$.tw. (1360) 36 (sEcadherin or soluble E\u2010cadherin).tw. (97) 37 (sEselectin or soluble E\u2010selectin).tw. (713) 38 exp t\u2010lymphocytes/ or exp natural killer t\u2010cells/ (284378) 39 Immune cells alteration$.tw. (1) 40 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (22494) 41 Total complement level$.tw. (24) 42 Autoantibodies.tw. (35161) 43 exp Antibodies, Antiphospholipid/ (7759) 44 Anti\u2010endometrial.tw. (22) 45 Antiphospholipid$.tw. (10351) 46 exp hla antigens/ or exp hla\u2010a1 antigen/ or exp hla\u2010a2 antigen/ (66724) 47 (HLA or human leucocyte antigen$).tw. (83856) 48 Anti\u2010laminin\u20101.tw. (33) 49 Anti\u2010thyroid.tw. (1478) 50 Anti\u2010Thomsen Friedenreich antigen$.tw. (8) 51 Anti\u2010transferrin.tw. (284) 52 Anti\u2010LDL.tw. (183) 53 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (3) 54 interleukin$.tw. (184697) 55 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (46) 56 (MIF or migration inhibitory factor$).tw. (4718) 57 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (1428) 58 Fas ligand$.tw. (6204) 59 Endometrial marker$.tw. (11) 60 CAMs.tw. (1823) 61 cell adhesion molecule$.tw. (22033) 62 exp Integrins/ (46487) 63 Integrin$.tw. (42447) 64 Selectin$.tw. (58540) 65 Cadherin$.tw. (22688) 66 Aromatase P450.tw. (182) 67 estrogen receptor$.tw. (41210) 68 progesterone receptor$.tw. (17437) 69 MTMMP$.tw. (7) 70 cyr61.tw. (620) 71 exp Cysteine\u2010Rich Protein 61/ (425) 72 cysteine\u2010rich heparin\u2010binding protein$.tw. (9) 73 (ANXA 1 or ANXA1).tw. (355) 74 (Annexin 1 or Annexin1).tw. (358) 75 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2190) 76 serum marker$.tw. (5721) 77 neural marker$.tw. (1026) 78 cell surface marker$.tw. (4751) 79 inflammatory marker$.tw. (12244) 80 microarray$.tw. (81764) 81 microRNA$.tw. (35967) 82 proteomic$.tw. (49911) 83 genomic$.tw. (205064) 84 (endometri$ adj2 biops$).tw. (3518) 85 Follistatin$.tw. (1762) 86 Vascular Endothelial Growth Factor A/ (38477) 87 Vitamin D\u2010Binding Protein/ (1356) 88 exp Cytokines/ (575020) 89 exp interleukins/ or exp interleukin\u20101/ or exp interleukin\u20106/ or exp interleukin\u20108/ or exp interleukin\u201012/ or exp interleukin\u201013/ (197567)  90 exp Epidermal Growth Factor/ (21875) 91 exp Fibroblast Growth Factors/ (26259) 92 Platelet\u2010Derived Growth Factor/ (11355) 93 Keratin\u201019/ (1179) 94 exp Clinical Laboratory Techniques/ (2203416) 95 (Luteinizing Hormone$ or LH).tw. (57796) 96 cytokeratin\u201019.tw. (1538) 97 (VDBP or vitamin D\u2010binding protein$).tw. (1262) 98 urinary peptide$.tw. (148) 99 VDBP\u2010Cr.tw. (1) 100 urinary VDBP corrected for creatinine expression.tw. (1) 101 urinary marker$.tw. (679) 102 or/1\u2010101 (4283825) 103 Endometriosis/di [Diagnosis] (3449) 104 102 or 103 (4286552) 105 exp Endometriosis/ (17833) 106 Endometrio$.tw. (22478) 107 105 or 106 (26003) 108 104 and 107 (10936) 109 (animals not (humans and animals)).sh. (4004321) 110 108 not 109 (10539) 111 (201501$ or 201502$ or 201503$ or 201504$).ed. (322721) 112 110 and 111 (215)",
        "Database: MEDLINE (Ovid) <1946 to February, week 2 2015 (16.2.2015)> >": "Ovid MEDLINE(R) In\u2010Process & Other Non\u2010Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)  Search Strategy: 1 (biomarker$ or marker$).tw. (605002) 2 Laboratory Test$.tw. (29839) 3 growth factor$.tw. (272049) 4 scatter factor$.tw. (1287) 5 cytokine$.tw. (250618) 6 hepatocyte growth factor.tw. (8053) 7 (FGF or fibroblast growth factor$).tw. (31798) 8 (PDGF or platelet derived growth factor$).tw. (19864) 9 (EGF or epidermal growth factor$).tw. (58069) 10 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (43539) 11 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (281) 12 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (28842) 13 (EGFR or epidermal growth factor receptor$).tw. (41719) 14 (VEGF or vascular endothelial growth factor$).tw. (53588) 15 exp Luteinizing Hormone/bl (Blood) (24587) 16 leptin$.tw. (24994) 17 exp Progesterone/bl (Blood) (18412) 18 Proteolytic enzyme$.tw. (9768) 19 exp matrix metalloproteinase 1/ or exp matrix metalloproteinase 2/ or exp matrix metalloproteinase 3/ or exp matrix metalloproteinase 9/ (22968)  20 matrix metalloproteinase$.tw. (34522) 21 MMP$.tw. (44439) 22 TIMP$.tw. (10777) 23 exp \"tissue inhibitor of metalloproteinase\u20101\"/ or exp \"tissue inhibitor of metalloproteinase\u20102\"/ (6146)  24 exp Glycoproteins/ (637149) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (6761) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (4194) 27 (PP 14 or PP14).tw. (229) 28 serum placental protein$.tw. (33) 29 exp Follistatin/ (1134) 30 Osteopontin$.tw. (6769) 31 exp intercellular adhesion molecule\u20101/ or exp selectins/ (25302) 32 soluble intercellular adhesion.tw. (1588) 33 Soluble adhesion molecule$.tw. (779) 34 sICAM.tw. (2258) 35 sVCAM$.tw. (1277) 36 (sEcadherin or soluble E\u2010cadherin).tw. (95) 37 (sEselectin or soluble E\u2010selectin).tw. (689) 38 exp t\u2010lymphocytes/ or exp natural killer t\u2010cells/ (272580) 39 Immune cells alteration$.tw. (1) 40 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (21275) 41 Total complement level$.tw. (23) 42 Autoantibodies.tw. (33457) 43 exp Antibodies, Antiphospholipid/ (7522) 44 Anti\u2010endometrial.tw. (23) 45 Antiphospholipid$.tw. (9974) 46 exp hla antigens/ or exp hla\u2010a1 antigen/ or exp hla\u2010a2 antigen/ (64462) 47 (HLA or human leucocyte antigen$).tw. (80501) 48 Anti\u2010laminin\u20101.tw. (33) 49 Anti\u2010thyroid.tw. (1414) 50 Anti\u2010Thomsen Friedenreich antigen$.tw. (6) 51 Anti\u2010transferrin.tw. (275) 52 Anti\u2010LDL.tw. (181) 53 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (3) 54 interleukin$.tw. (175195) 55 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (44) 56 (MIF or migration inhibitory factor$).tw. (4479) 57 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (1344) 58 Fas ligand$.tw. (6032) 59 Endometrial marker$.tw. (11) 60 CAMs.tw. (1756) 61 cell adhesion molecule$.tw. (20903) 62 exp Integrins/ (44414) 63 Integrin$.tw. (39960) 64 Selectin$.tw. (55426) 65 Cadherin$.tw. (20780) 66 Aromatase P450.tw. (180) 67 estrogen receptor$.tw. (38819) 68 progesterone receptor$.tw. (16623) 69 MTMMP$.tw. (7) 70 cyr61.tw. (559) 71 exp Cysteine\u2010Rich Protein 61/ (386) 72 cysteine\u2010rich heparin\u2010binding protein$.tw. (9) 73 (ANXA 1 or ANXA1).tw. (313) 74 (Annexin 1 or Annexin1).tw. (339) 75 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2096) 76 serum marker$.tw. (5429) 77 neural marker$.tw. (925) 78 cell surface marker$.tw. (4456) 79 inflammatory marker$.tw. (10916) 80 microarray$.tw. (75404) 81 microRNA$.tw. (29731) 82 proteomic$.tw. (45292) 83 genomic$.tw. (190985) 84 (endometri$ adj2 biops$).tw. (3411) 85 Follistatin$.tw. (1663) 86 Vascular Endothelial Growth Factor A/ (35738) 87 Vitamin D\u2010Binding Protein/ (1282) 88 exp Cytokines/ (547522) 89 exp interleukins/ or exp interleukin\u20101/ or exp interleukin\u20106/ or exp interleukin\u20108/ or exp interleukin\u201012/ or exp interleukin\u201013/ (188479)  90 exp Epidermal Growth Factor/ (21298) 91 exp Fibroblast Growth Factors/ (25075) 92 Platelet\u2010Derived Growth Factor/ (11030) 93 Keratin\u201019/ (1090) 94 exp Clinical Laboratory Techniques/ (2132820) 95 (Luteinizing Hormone$ or LH).tw. (56679) 96 cytokeratin\u201019.tw. (1469) 97 (VDBP or vitamin D\u2010binding protein$).tw. (1158) 98 urinary peptide$.tw. (137) 99 VDBP\u2010Cr.tw. (1) 100 urinary VDBP corrected for creatinine expression.tw. (1) 101 urinary marker$.tw. (638) 102 or/1\u2010101 (4086291) 103 Endometriosis/di (Diagnosis) (3354) 104 102 or 103 (4088946) 105 exp Endometriosis/ (17244) 106 Endometrio$.tw. (21492) 107 105 or 106 (24940) 108 104 and 107 (10490) 109 (animals not (humans and animals)).sh. (3892900) 110 108 not 109 (10113) Additional search February 2015 \u2010 May 2015  Ovid MEDLINE(R) In\u2010Process & Other Non\u2010Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present (3.9.2015)>  Search Strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 (biomarker$ or marker$).tw. (652345) 2 Laboratory Test$.tw. (31389) 3 growth factor$.tw. (287701) 4 scatter factor$.tw. (1326) 5 cytokine$.tw. (267766) 6 hepatocyte growth factor.tw. (8585) 7 (FGF or fibroblast growth factor$).tw. (33674) 8 (PDGF or platelet derived growth factor$).tw. (20842) 9 (EGF or epidermal growth factor$).tw. (61625) 10 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (45386) 11 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (306) 12 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (30559) 13 (EGFR or epidermal growth factor receptor$).tw. (46446) 14 (VEGF or vascular endothelial growth factor$).tw. (58203) 15 exp Luteinizing Hormone/bl [Blood] (24870) 16 leptin$.tw. (26783) 17 exp Progesterone/bl [Blood] (18699) 18 Proteolytic enzyme$.tw. (9992) 19 exp matrix metalloproteinase 1/ or exp matrix metalloproteinase 2/ or exp matrix metalloproteinase 3/ or exp matrix metalloproteinase 9/ (24504)  20 matrix metalloproteinase$.tw. (37055) 21 MMP$.tw. (47849) 22 TIMP$.tw. (11419) 23 exp \"tissue inhibitor of metalloproteinase\u20101\"/ or exp \"tissue inhibitor of metalloproteinase\u20102\"/ (6447)  24 exp Glycoproteins/ (662211) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (7058) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (4399) 27 (PP 14 or PP14).tw. (232) 28 serum placental protein$.tw. (34) 29 exp Follistatin/ (1180) 30 Osteopontin$.tw. (7267) 31 exp intercellular adhesion molecule\u20101/ or exp selectins/ (26225) 32 soluble intercellular adhesion.tw. (1663) 33 Soluble adhesion molecule$.tw. (795) 34 sICAM.tw. (2374) 35 sVCAM$.tw. (1360) 36 (sEcadherin or soluble E\u2010cadherin).tw. (97) 37 (sEselectin or soluble E\u2010selectin).tw. (713) 38 exp t\u2010lymphocytes/ or exp natural killer t\u2010cells/ (284378) 39 Immune cells alteration$.tw. (1) 40 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (22494) 41 Total complement level$.tw. (24) 42 Autoantibodies.tw. (35161) 43 exp Antibodies, Antiphospholipid/ (7759) 44 Anti\u2010endometrial.tw. (22) 45 Antiphospholipid$.tw. (10351) 46 exp hla antigens/ or exp hla\u2010a1 antigen/ or exp hla\u2010a2 antigen/ (66724) 47 (HLA or human leucocyte antigen$).tw. (83856) 48 Anti\u2010laminin\u20101.tw. (33) 49 Anti\u2010thyroid.tw. (1478) 50 Anti\u2010Thomsen Friedenreich antigen$.tw. (8) 51 Anti\u2010transferrin.tw. (284) 52 Anti\u2010LDL.tw. (183) 53 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (3) 54 interleukin$.tw. (184697) 55 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (46) 56 (MIF or migration inhibitory factor$).tw. (4718) 57 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (1428) 58 Fas ligand$.tw. (6204) 59 Endometrial marker$.tw. (11) 60 CAMs.tw. (1823) 61 cell adhesion molecule$.tw. (22033) 62 exp Integrins/ (46487) 63 Integrin$.tw. (42447) 64 Selectin$.tw. (58540) 65 Cadherin$.tw. (22688) 66 Aromatase P450.tw. (182) 67 estrogen receptor$.tw. (41210) 68 progesterone receptor$.tw. (17437) 69 MTMMP$.tw. (7) 70 cyr61.tw. (620) 71 exp Cysteine\u2010Rich Protein 61/ (425) 72 cysteine\u2010rich heparin\u2010binding protein$.tw. (9) 73 (ANXA 1 or ANXA1).tw. (355) 74 (Annexin 1 or Annexin1).tw. (358) 75 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2190) 76 serum marker$.tw. (5721) 77 neural marker$.tw. (1026) 78 cell surface marker$.tw. (4751) 79 inflammatory marker$.tw. (12244) 80 microarray$.tw. (81764) 81 microRNA$.tw. (35967) 82 proteomic$.tw. (49911) 83 genomic$.tw. (205064) 84 (endometri$ adj2 biops$).tw. (3518) 85 Follistatin$.tw. (1762) 86 Vascular Endothelial Growth Factor A/ (38477) 87 Vitamin D\u2010Binding Protein/ (1356) 88 exp Cytokines/ (575020) 89 exp interleukins/ or exp interleukin\u20101/ or exp interleukin\u20106/ or exp interleukin\u20108/ or exp interleukin\u201012/ or exp interleukin\u201013/ (197567)  90 exp Epidermal Growth Factor/ (21875) 91 exp Fibroblast Growth Factors/ (26259) 92 Platelet\u2010Derived Growth Factor/ (11355) 93 Keratin\u201019/ (1179) 94 exp Clinical Laboratory Techniques/ (2203416) 95 (Luteinizing Hormone$ or LH).tw. (57796) 96 cytokeratin\u201019.tw. (1538) 97 (VDBP or vitamin D\u2010binding protein$).tw. (1262) 98 urinary peptide$.tw. (148) 99 VDBP\u2010Cr.tw. (1) 100 urinary VDBP corrected for creatinine expression.tw. (1) 101 urinary marker$.tw. (679) 102 or/1\u2010101 (4283825) 103 Endometriosis/di [Diagnosis] (3449) 104 102 or 103 (4286552) 105 exp Endometriosis/ (17833) 106 Endometrio$.tw. (22478) 107 105 or 106 (26003) 108 104 and 107 (10936) 109 (animals not (humans and animals)).sh. (4004321) 110 108 not 109 (10539) 111 (201501$ or 201502$ or 201503$ or 201504$).ed. (322721) 112 110 and 111 (215)",
        "Appendix 4. Search strategy for EMBASE (OVID platform)": "Database: EMBASE (Ovid) <1980 to 2015 Week 07 (16.02.2015)> Search strategy: 1 Laboratory Test$.tw. (41662) 2 growth factor$.tw. (318593) 3 scatter factor$.tw. (1388) 4 cytokine$.tw. (322134) 5 hepatocyte growth factor.tw. (9594) 6 (FGF or fibroblast growth factor$).tw. (37191) 7 (PDGF or platelet derived growth factor$).tw. (23530) 8 (EGF or epidermal growth factor$).tw. (69553) 9 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (49806) 10 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (542) 11 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (30820) 12 (EGFR or epidermal growth factor receptor$).tw. (64664) 13 (VEGF or vascular endothelial growth factor$).tw. (73191) 14 exp luteinizing hormone/ec (Endogenous Compound) (21924) 15 leptin$.tw. (32576) 16 exp progesterone blood level/ or exp progesterone urine level/ (6285) 17 Proteolytic enzyme$.tw. (9643) 18 exp matrix metalloproteinase/ (19364) 19 matrix metalloproteinase$.tw. (41445) 20 MMP$.tw. (58466) 21 TIMP$.tw. (14174) 22 exp \"tissue inhibitor of metalloproteinase 2\"/ (4824) 23 exp \"tissue inhibitor of metalloproteinase 1\"/ (8779) 24 exp glycoprotein/ec (Endogenous Compound) (246077) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (9536) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (6054) 27 (PP 14 or PP14).tw. (244) 28 serum placental protein$.tw. (43) 29 exp follistatin/ (2148) 30 Osteopontin$.tw. (8475) 31 exp intercellular adhesion molecule 1/ (32066) 32 exp selectin/ (3082) 33 soluble intercellular adhesion.tw. (1788) 34 Soluble adhesion molecule$.tw. (919) 35 sICAM.tw. (2888) 36 sVCAM$.tw. (1793) 37 (sEcadherin or soluble E\u2010cadherin).tw. (120) 38 (sEselectin or soluble E\u2010selectin).tw. (822) 39 exp T lymphocyte/ (374675) 40 exp natural killer T cell/ (5800) 41 Immune cells alteration$.tw. (6) 42 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (24786) 43 Total complement level$.tw. (20) 44 Autoantibodies.tw. (42037) 45 exp phospholipid antibody/ (9920) 46 Anti\u2010endometrial.tw. (23) 47 Antiphospholipid$.tw. (13777) 48 exp HLA antigen/ (81011) 49 exp HLA A1 antigen/ (597) 50 exp HLA A2 antigen/ (3288) 51 (HLA or human leucocyte antigen$).tw. (104497) 52 Anti\u2010laminin\u20101.tw. (43) 53 Anti\u2010thyroid.tw. (1873) 54 Anti\u2010Thomsen Friedenreich antigen$.tw. (5) 55 Anti\u2010transferrin.tw. (290) 56 Anti\u2010LDL.tw. (186) 57 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (4) 58 interleukin$.tw. (199692) 59 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (112) 60 (MIF or migration inhibitory factor$).tw. (5063) 61 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (5998) 62 Fas ligand$.tw. (6708) 63 Endometrial marker$.tw. (18) 64 CAMs.tw. (2100) 65 cell adhesion molecule$.tw. (24039) 66 exp integrin/ (29036) 67 Integrin$.tw. (48293) 68 Selectin$.tw. (67300) 69 Cadherin$.tw. (27150) 70 Aromatase P450.tw. (202) 71 estrogen receptor$.tw. (46656) 72 progesterone receptor$.tw. (19861) 73 MTMMP$.tw. (15) 74 cyr61.tw. (755) 75 exp cysteine rich protein 61/ (753) 76 cysteine\u2010rich heparin\u2010binding protein$.tw. (12) 77 (ANXA 1 or ANXA1).tw. (452) 78 (Annexin 1 or Annexin1).tw. (425) 79 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2620) 80 serum marker$.tw. (7720) 81 neural marker$.tw. (1119) 82 cell surface marker$.tw. (5851) 83 inflammatory marker$.tw. (17339) 84 microarray$.tw. (101846) 85 microRNA$.tw. (40082) 86 proteomic$.tw. (55191) 87 genomic$.tw. (217184) 88 (endometri$ adj2 biops$).tw. (4369) 89 Follistatin$.tw. (1945) 90 exp vasculotropin/ (69810) 91 Vascular Endothelial Growth Factor A.tw. (2275) 92 exp vitamin D binding protein/ (2064) 93 exp cytokine/ (1034772) 94 exp interleukin derivative/ (2790) 95 exp interleukin 1/ (48499) 96 exp interleukin 6/ (136328) 97 exp interleukin 8/ (48884) 98 exp interleukin 12/ (31842) 99 exp interleukin 13/ (13584) 100 exp epidermal growth factor/ (32130) 101 exp fibroblast growth factor/ (13858) 102 cytokeratin 19/ (3601) 103 platelet derived growth factor/ (18930) 104 cytokeratin\u201019.tw. (1918) 105 (VDBP or vitamin D\u2010binding protein$).tw. (1413) 106 urinary peptide$.tw. (174) 107 VDBP\u2010Cr.tw. (1) 108 urinary VDBP corrected for creatinine expression.tw. (1) 109 urinary marker$.tw. (830) 110 exp blood analysis/ (118854) 111 exp endometrium biopsy/ (4988) 112 exp urinalysis/ or exp biological marker/ (210153) 113 (biomarker or biomarkers).tw. (159748) 114 or/1\u2010113 (2734501) 115 endometriosis/di (Diagnosis) (4979) 116 114 or 115 (2738583) 117 exp endometriosis/ (25923) 118 Endometriosis.tw. (22110) 119 117 or 118 (27911) 120 116 and 119 (10326) 121 Animal/ not Human/ (1204497) 122 120 not 121 (10279) Additional search February 2015 \u2010 May 2015  Embase <1980 to 2015 Week 35 (3.09.2015)> Search Strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 Laboratory Test$.tw. (44290) 2 growth factor$.tw. (335543) 3 scatter factor$.tw. (1407) 4 cytokine$.tw. (343623) 5 hepatocyte growth factor.tw. (10104) 6 (FGF or fibroblast growth factor$).tw. (39159) 7 (PDGF or platelet derived growth factor$).tw. (24591) 8 (EGF or epidermal growth factor$).tw. (73599) 9 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (51838) 10 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (583) 11 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (32580) 12 (EGFR or epidermal growth factor receptor$).tw. (71526) 13 (VEGF or vascular endothelial growth factor$).tw. (79087) 14 exp luteinizing hormone/ec [Endogenous Compound] (22767) 15 leptin$.tw. (34921) 16 exp progesterone blood level/ or exp progesterone urine level/ (6534) 17 Proteolytic enzyme$.tw. (9903) 18 exp matrix metalloproteinase/ (20462) 19 matrix metalloproteinase$.tw. (44380) 20 MMP$.tw. (63208) 21 TIMP$.tw. (15146) 22 exp \"tissue inhibitor of metalloproteinase 2\"/ (5136) 23 exp \"tissue inhibitor of metalloproteinase 1\"/ (9381) 24 exp glycoprotein/ec [Endogenous Compound] (260024) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (10051) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (6446) 27 (PP 14 or PP14).tw. (243) 28 serum placental protein$.tw. (44) 29 exp follistatin/ (2283) 30 Osteopontin$.tw. (9173) 31 exp intercellular adhesion molecule 1/ (33492) 32 exp selectin/ (3217) 33 soluble intercellular adhesion.tw. (1865) 34 Soluble adhesion molecule$.tw. (944) 35 sICAM.tw. (3049) 36 sVCAM$.tw. (1924) 37 (sEcadherin or soluble E\u2010cadherin).tw. (125) 38 (sEselectin or soluble E\u2010selectin).tw. (861) 39 exp T lymphocyte/ (394405) 40 exp natural killer T cell/ (6310) 41 Immune cells alteration$.tw. (6) 42 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (26082) 43 Total complement level$.tw. (20) 44 Autoantibodies.tw. (44153) 45 exp phospholipid antibody/ (10362) 46 Anti\u2010endometrial.tw. (25) 47 Antiphospholipid$.tw. (14399) 48 exp HLA antigen/ (83748) 49 exp HLA A1 antigen/ (622) 50 exp HLA A2 antigen/ (3409) 51 (HLA or human leucocyte antigen$).tw. (109332) 52 Anti\u2010laminin\u20101.tw. (43) 53 Anti\u2010thyroid.tw. (2059) 54 Anti\u2010Thomsen Friedenreich antigen$.tw. (7) 55 Anti\u2010transferrin.tw. (297) 56 Anti\u2010LDL.tw. (191) 57 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (4) 58 interleukin$.tw. (210083) 59 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (114) 60 (MIF or migration inhibitory factor$).tw. (5342) 61 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (6488) 62 Fas ligand$.tw. (6895) 63 Endometrial marker$.tw. (18) 64 CAMs.tw. (2198) 65 cell adhesion molecule$.tw. (25207) 66 exp integrin/ (30330) 67 Integrin$.tw. (50938) 68 Selectin$.tw. (71624) 69 Cadherin$.tw. (29496) 70 Aromatase P450.tw. (207) 71 estrogen receptor$.tw. (49530) 72 progesterone receptor$.tw. (21068) 73 MTMMP$.tw. (16) 74 cyr61.tw. (822) 75 exp cysteine rich protein 61/ (829) 76 cysteine\u2010rich heparin\u2010binding protein$.tw. (12) 77 (ANXA 1 or ANXA1).tw. (500) 78 (Annexin 1 or Annexin1).tw. (440) 79 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2760) 80 serum marker$.tw. (8158) 81 neural marker$.tw. (1234) 82 cell surface marker$.tw. (6222) 83 inflammatory marker$.tw. (19492) 84 microarray$.tw. (110181) 85 microRNA$.tw. (47554) 86 proteomic$.tw. (60599) 87 genomic$.tw. (233444) 88 (endometri$ adj2 biops$).tw. (4589) 89 Follistatin$.tw. (2081) 90 exp vasculotropin/ (74115) 91 Vascular Endothelial Growth Factor A.tw. (2526) 92 exp vitamin D binding protein/ (2196) 93 exp cytokine/ (1094317) 94 exp interleukin derivative/ (3281) 95 exp interleukin 1/ (50850) 96 exp interleukin 6/ (147379) 97 exp interleukin 8/ (52281) 98 exp interleukin 12/ (33479) 99 exp interleukin 13/ (14685) 100 exp epidermal growth factor/ (33057) 101 exp fibroblast growth factor/ (14499) 102 cytokeratin 19/ (3886) 103 platelet derived growth factor/ (19655) 104 cytokeratin\u201019.tw. (2030) 105 (VDBP or vitamin D\u2010binding protein$).tw. (1520) 106 urinary peptide$.tw. (189) 107 VDBP\u2010Cr.tw. (1) 108 urinary VDBP corrected for creatinine expression.tw. (1) 109 urinary marker$.tw. (883) 110 exp blood analysis/ (124468) 111 exp endometrium biopsy/ (5197) 112 exp urinalysis/ or exp biological marker/ (232619) 113 (biomarker or biomarkers).tw. (182609) 114 or/1\u2010113 (2911073) 115 endometriosis/di [Diagnosis] (5173) 116 114 or 115 (2915302) 117 exp endometriosis/ (27433) 118 Endometriosis.tw. (23449) 119 117 or 118 (29532) 120 116 and 119 (10922) 121 Animal/ not Human/ (1261620) 122 120 not 121 (10862) 123 (201501$ or 201502$ or 201503$ or 201504$).em. (49200) 124 122 and 123 (34)",
        "Database: EMBASE (Ovid) <1980 to 2015 Week 07 (16.02.2015)>": "Search strategy: 1 Laboratory Test$.tw. (41662) 2 growth factor$.tw. (318593) 3 scatter factor$.tw. (1388) 4 cytokine$.tw. (322134) 5 hepatocyte growth factor.tw. (9594) 6 (FGF or fibroblast growth factor$).tw. (37191) 7 (PDGF or platelet derived growth factor$).tw. (23530) 8 (EGF or epidermal growth factor$).tw. (69553) 9 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (49806) 10 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (542) 11 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (30820) 12 (EGFR or epidermal growth factor receptor$).tw. (64664) 13 (VEGF or vascular endothelial growth factor$).tw. (73191) 14 exp luteinizing hormone/ec (Endogenous Compound) (21924) 15 leptin$.tw. (32576) 16 exp progesterone blood level/ or exp progesterone urine level/ (6285) 17 Proteolytic enzyme$.tw. (9643) 18 exp matrix metalloproteinase/ (19364) 19 matrix metalloproteinase$.tw. (41445) 20 MMP$.tw. (58466) 21 TIMP$.tw. (14174) 22 exp \"tissue inhibitor of metalloproteinase 2\"/ (4824) 23 exp \"tissue inhibitor of metalloproteinase 1\"/ (8779) 24 exp glycoprotein/ec (Endogenous Compound) (246077) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (9536) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (6054) 27 (PP 14 or PP14).tw. (244) 28 serum placental protein$.tw. (43) 29 exp follistatin/ (2148) 30 Osteopontin$.tw. (8475) 31 exp intercellular adhesion molecule 1/ (32066) 32 exp selectin/ (3082) 33 soluble intercellular adhesion.tw. (1788) 34 Soluble adhesion molecule$.tw. (919) 35 sICAM.tw. (2888) 36 sVCAM$.tw. (1793) 37 (sEcadherin or soluble E\u2010cadherin).tw. (120) 38 (sEselectin or soluble E\u2010selectin).tw. (822) 39 exp T lymphocyte/ (374675) 40 exp natural killer T cell/ (5800) 41 Immune cells alteration$.tw. (6) 42 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (24786) 43 Total complement level$.tw. (20) 44 Autoantibodies.tw. (42037) 45 exp phospholipid antibody/ (9920) 46 Anti\u2010endometrial.tw. (23) 47 Antiphospholipid$.tw. (13777) 48 exp HLA antigen/ (81011) 49 exp HLA A1 antigen/ (597) 50 exp HLA A2 antigen/ (3288) 51 (HLA or human leucocyte antigen$).tw. (104497) 52 Anti\u2010laminin\u20101.tw. (43) 53 Anti\u2010thyroid.tw. (1873) 54 Anti\u2010Thomsen Friedenreich antigen$.tw. (5) 55 Anti\u2010transferrin.tw. (290) 56 Anti\u2010LDL.tw. (186) 57 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (4) 58 interleukin$.tw. (199692) 59 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (112) 60 (MIF or migration inhibitory factor$).tw. (5063) 61 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (5998) 62 Fas ligand$.tw. (6708) 63 Endometrial marker$.tw. (18) 64 CAMs.tw. (2100) 65 cell adhesion molecule$.tw. (24039) 66 exp integrin/ (29036) 67 Integrin$.tw. (48293) 68 Selectin$.tw. (67300) 69 Cadherin$.tw. (27150) 70 Aromatase P450.tw. (202) 71 estrogen receptor$.tw. (46656) 72 progesterone receptor$.tw. (19861) 73 MTMMP$.tw. (15) 74 cyr61.tw. (755) 75 exp cysteine rich protein 61/ (753) 76 cysteine\u2010rich heparin\u2010binding protein$.tw. (12) 77 (ANXA 1 or ANXA1).tw. (452) 78 (Annexin 1 or Annexin1).tw. (425) 79 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2620) 80 serum marker$.tw. (7720) 81 neural marker$.tw. (1119) 82 cell surface marker$.tw. (5851) 83 inflammatory marker$.tw. (17339) 84 microarray$.tw. (101846) 85 microRNA$.tw. (40082) 86 proteomic$.tw. (55191) 87 genomic$.tw. (217184) 88 (endometri$ adj2 biops$).tw. (4369) 89 Follistatin$.tw. (1945) 90 exp vasculotropin/ (69810) 91 Vascular Endothelial Growth Factor A.tw. (2275) 92 exp vitamin D binding protein/ (2064) 93 exp cytokine/ (1034772) 94 exp interleukin derivative/ (2790) 95 exp interleukin 1/ (48499) 96 exp interleukin 6/ (136328) 97 exp interleukin 8/ (48884) 98 exp interleukin 12/ (31842) 99 exp interleukin 13/ (13584) 100 exp epidermal growth factor/ (32130) 101 exp fibroblast growth factor/ (13858) 102 cytokeratin 19/ (3601) 103 platelet derived growth factor/ (18930) 104 cytokeratin\u201019.tw. (1918) 105 (VDBP or vitamin D\u2010binding protein$).tw. (1413) 106 urinary peptide$.tw. (174) 107 VDBP\u2010Cr.tw. (1) 108 urinary VDBP corrected for creatinine expression.tw. (1) 109 urinary marker$.tw. (830) 110 exp blood analysis/ (118854) 111 exp endometrium biopsy/ (4988) 112 exp urinalysis/ or exp biological marker/ (210153) 113 (biomarker or biomarkers).tw. (159748) 114 or/1\u2010113 (2734501) 115 endometriosis/di (Diagnosis) (4979) 116 114 or 115 (2738583) 117 exp endometriosis/ (25923) 118 Endometriosis.tw. (22110) 119 117 or 118 (27911) 120 116 and 119 (10326) 121 Animal/ not Human/ (1204497) 122 120 not 121 (10279) Additional search February 2015 \u2010 May 2015  Embase <1980 to 2015 Week 35 (3.09.2015)> Search Strategy: \u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010\u2010 1 Laboratory Test$.tw. (44290) 2 growth factor$.tw. (335543) 3 scatter factor$.tw. (1407) 4 cytokine$.tw. (343623) 5 hepatocyte growth factor.tw. (10104) 6 (FGF or fibroblast growth factor$).tw. (39159) 7 (PDGF or platelet derived growth factor$).tw. (24591) 8 (EGF or epidermal growth factor$).tw. (73599) 9 (IGF\u2010I or insulin\u2010like growth factor$ or IGF1).tw. (51838) 10 (TGF\u2010a or transforming growth factor alfa or TGFa).tw. (583) 11 (TGF\u2010b or transforming growth factor beta or TGFb).tw. (32580) 12 (EGFR or epidermal growth factor receptor$).tw. (71526) 13 (VEGF or vascular endothelial growth factor$).tw. (79087) 14 exp luteinizing hormone/ec [Endogenous Compound] (22767) 15 leptin$.tw. (34921) 16 exp progesterone blood level/ or exp progesterone urine level/ (6534) 17 Proteolytic enzyme$.tw. (9903) 18 exp matrix metalloproteinase/ (20462) 19 matrix metalloproteinase$.tw. (44380) 20 MMP$.tw. (63208) 21 TIMP$.tw. (15146) 22 exp \"tissue inhibitor of metalloproteinase 2\"/ (5136) 23 exp \"tissue inhibitor of metalloproteinase 1\"/ (9381) 24 exp glycoprotein/ec [Endogenous Compound] (260024) 25 (Ca\u2010125 or Ca125 or cancer antigen 125).tw. (10051) 26 (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109).tw. (6446) 27 (PP 14 or PP14).tw. (243) 28 serum placental protein$.tw. (44) 29 exp follistatin/ (2283) 30 Osteopontin$.tw. (9173) 31 exp intercellular adhesion molecule 1/ (33492) 32 exp selectin/ (3217) 33 soluble intercellular adhesion.tw. (1865) 34 Soluble adhesion molecule$.tw. (944) 35 sICAM.tw. (3049) 36 sVCAM$.tw. (1924) 37 (sEcadherin or soluble E\u2010cadherin).tw. (125) 38 (sEselectin or soluble E\u2010selectin).tw. (861) 39 exp T lymphocyte/ (394405) 40 exp natural killer T cell/ (6310) 41 Immune cells alteration$.tw. (6) 42 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (26082) 43 Total complement level$.tw. (20) 44 Autoantibodies.tw. (44153) 45 exp phospholipid antibody/ (10362) 46 Anti\u2010endometrial.tw. (25) 47 Antiphospholipid$.tw. (14399) 48 exp HLA antigen/ (83748) 49 exp HLA A1 antigen/ (622) 50 exp HLA A2 antigen/ (3409) 51 (HLA or human leucocyte antigen$).tw. (109332) 52 Anti\u2010laminin\u20101.tw. (43) 53 Anti\u2010thyroid.tw. (2059) 54 Anti\u2010Thomsen Friedenreich antigen$.tw. (7) 55 Anti\u2010transferrin.tw. (297) 56 Anti\u2010LDL.tw. (191) 57 (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein).tw. (4) 58 interleukin$.tw. (210083) 59 (MCP\u2010I or monocyte chemoattractant protein\u2010I).tw. (114) 60 (MIF or migration inhibitory factor$).tw. (5342) 61 (TNF\u2010a or tumour necrosis factor$ alfa).tw. (6488) 62 Fas ligand$.tw. (6895) 63 Endometrial marker$.tw. (18) 64 CAMs.tw. (2198) 65 cell adhesion molecule$.tw. (25207) 66 exp integrin/ (30330) 67 Integrin$.tw. (50938) 68 Selectin$.tw. (71624) 69 Cadherin$.tw. (29496) 70 Aromatase P450.tw. (207) 71 estrogen receptor$.tw. (49530) 72 progesterone receptor$.tw. (21068) 73 MTMMP$.tw. (16) 74 cyr61.tw. (822) 75 exp cysteine rich protein 61/ (829) 76 cysteine\u2010rich heparin\u2010binding protein$.tw. (12) 77 (ANXA 1 or ANXA1).tw. (500) 78 (Annexin 1 or Annexin1).tw. (440) 79 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2760) 80 serum marker$.tw. (8158) 81 neural marker$.tw. (1234) 82 cell surface marker$.tw. (6222) 83 inflammatory marker$.tw. (19492) 84 microarray$.tw. (110181) 85 microRNA$.tw. (47554) 86 proteomic$.tw. (60599) 87 genomic$.tw. (233444) 88 (endometri$ adj2 biops$).tw. (4589) 89 Follistatin$.tw. (2081) 90 exp vasculotropin/ (74115) 91 Vascular Endothelial Growth Factor A.tw. (2526) 92 exp vitamin D binding protein/ (2196) 93 exp cytokine/ (1094317) 94 exp interleukin derivative/ (3281) 95 exp interleukin 1/ (50850) 96 exp interleukin 6/ (147379) 97 exp interleukin 8/ (52281) 98 exp interleukin 12/ (33479) 99 exp interleukin 13/ (14685) 100 exp epidermal growth factor/ (33057) 101 exp fibroblast growth factor/ (14499) 102 cytokeratin 19/ (3886) 103 platelet derived growth factor/ (19655) 104 cytokeratin\u201019.tw. (2030) 105 (VDBP or vitamin D\u2010binding protein$).tw. (1520) 106 urinary peptide$.tw. (189) 107 VDBP\u2010Cr.tw. (1) 108 urinary VDBP corrected for creatinine expression.tw. (1) 109 urinary marker$.tw. (883) 110 exp blood analysis/ (124468) 111 exp endometrium biopsy/ (5197) 112 exp urinalysis/ or exp biological marker/ (232619) 113 (biomarker or biomarkers).tw. (182609) 114 or/1\u2010113 (2911073) 115 endometriosis/di [Diagnosis] (5173) 116 114 or 115 (2915302) 117 exp endometriosis/ (27433) 118 Endometriosis.tw. (23449) 119 117 or 118 (29532) 120 116 and 119 (10922) 121 Animal/ not Human/ (1261620) 122 120 not 121 (10862) 123 (201501$ or 201502$ or 201503$ or 201504$).em. (49200) 124 122 and 123 (34)",
        "Appendix 5. Search strategy for CINAHL (EBSCO platform)": "Database: CINAHL Plus with Full Text (EBSCOhost) <1980 to 20.04.2015>  Search strategy:        #   Query   Results     S97   S3 AND S96   1131     S96   S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78 OR S79 OR S80 OR S81 OR S82 OR S83 OR S84 OR S85 OR S86 OR S87 OR S88 OR S89 OR S90 OR S91 OR S92 OR S93 OR S94 OR S95    341775     S95   TX urinary peptide*   1598     S94   TX (VDBP or vitamin D\u2010binding protein*)   134     S93   TX cytokeratin\u201019   109     S92   TX (Luteinizing Hormone* or LH)   18041     S91   (MH \"Diagnosis, Laboratory+\")   101773     S90   \"Keratin\u201019\"   2     S89   (MH \"Platelet\u2010Derived Growth Factor\")   394     S88   (MH \"Epidermal Growth Factors\")   1264     S87   (MH \"Interleukins\")   6584     S86   (MH \"Cytokines\")   6860     S85   TX Vitamin D\u2010Binding Protein   131     S84   (MH \"Vascular Endothelial Growth Factor A\")   194     S83   TX (endometri* N2 biops*)   432     S82   TX (endometri* adj2 biops*)   0     S81   TX genomic$   7487     S80   TX proteomic*   2434     S79   TX microRNA   824     S78   TX microarray   3123     S77   TX (PGP 95 or PGP95 or protein gene product*)   9925     S76   TX (Annexin 1 or Annexin1)   472     S75   TX (ANXA 1 or ANXA1)   41     S74   TX cysteine\u2010rich heparin\u2010binding protein*   12     S73   (MH \"Protein Array Analysis\")   73     S72   TX cyr61   34     S71   TX MTMMP*   0     S70   TX progesterone receptor*   1927     S69   TX estrogen receptor*   5193     S68   TX Aromatase P450   38     S67   TX Cadherin*   900     S66   TX Selectin*   28411     S65   TX Integrin*   1587     S64   TX cell adhesion molecule*   1578     S63   TX CAMs   550     S62   TX Endometrial marker*   54     S61   TX Fas ligand   338     S60   TX (TNF\u2010a or tumour necrosis factor* alfa)   1489     S59   TX (MIF or migration inhibitory factor*)   399     S58   TX (MCP\u2010I or monocyte chemoattractant protein\u2010I)   13     S57   TX interleukin   13809     S56   TX (Anti\u20102HSG or Heremans\u2010Schmidt glycoprotein)   7     S55   TX Anti\u2010LDL   9     S54   TX Anti\u2010transferrin   3     S53   TX Anti\u2010Thomsen Friedenreich antigen*   1     S52   TX Anti\u2010thyroid   109     S51   TX Anti\u2010laminin\u20101   15     S50   TX (HLA or human leucocyte antigen*)   4202     S49   (MM \"HLA Antigens\")   638     S48   TX Antiphospholipid*   1249     S47   TX Anti\u2010endometrial   34     S46   (MH \"Antibodies/BL/DU\")   1294     S45   TX Autoantibodies   4385     S43   TX Total complement level   3     S42   TX (T helper* or T supressor*)   2341     S41   TX Immune cells alteration*   24     S40   TX natural killer t\u2010cells   669     S39   (MM \"T Lymphocytes\")   2404     S38   TX (sEselectin or soluble E\u2010selectin)   91     S37   TX (sEcadherin or soluble E\u2010cadherin)   8     S36   TX sVCAM   100     S35   TX sICAM   173     S34   TX Soluble adhesion molecule   368     S33   TX soluble intercellular adhesion   237     S32   (MM \"Cell Adhesion Molecules\")   52     S31   TX Osteopontin*   416     S30   TX Follistatin   74     S29   TX serum placental protein*   11     S28   TX (Ca\u201019\u20109 or Ca19\u20109 or cancer antigen 19\u20109)   262     S27   TX (Ca\u2010125 or Ca125 or cancer antigen 125)   831     S26   (MM \"Glycoproteins/BL/DU\")   224     S25   TX tissue inhibitor of metalloproteinase   423     S24   TX TIMP*   1845     S23   TX MMP*   4244     S22   TX matrix metalloproteinase*   3325     S21   TX Proteolytic enzyme*   1461     S20   (MM \"Progesterone/BL/DU\")   51     S19   TX leptin*   3258     S18   (MM \"Luteinizing Hormone/BL/DU\")   38     S17   TX (VEGF or vascular endothelial growth factor*)   7166     S16   TX (EGFR or epidermal growth factor receptor*)   6188     S15   TX (TGF\u2010b or transforming growth factor beta or TGFb)   2972     S14   TX (TGF\u2010a or transforming growth factor alfa or TGFa)   464     S13   TX (IGF\u2010I or insulin\u2010like growth factor* or IGF1)   3588     S12   TX (EGF or epidermal growth factor*)   6250     S11   TX (PDGF or platelet derived growth factor*)   3195     S10   TX (FGF or fibroblast growth factor*)   3395     S9   TX hepatocyte growth factor*   880     S8   TX cytokine*   20821     S7   TX scatter factor*   1864     S6   TX growth factor*   76163     S5   TX Laboratory Test*   82732     S4   TX (biomarker* or marker*)   84857     S3   S1 OR S2   2841     S2   TX Endometrio*   2841     S1   (MM \"Endometriosis\")   889     S4   TX (biomarker* or marker*)   61,794     S3   S1 OR S2   2,174     S2   TX Endometrio*   2,174     S1   (MM \"Endometriosis\")   1,306",
        "Appendix 6. The search strategy for other databases": "Searches for clinical studies  Database: PsycINFO (Ovid) <1806 to April Week 2 2015 (20.04.2015)> Search strategy: 1. endometriosis.tw. (174)   Database: Web of Science Core Collection (Thomson Reuters) <1900 to Present (20.04.2015)> Search strategy: 1. Topic=(endometrio*) AND Topic=(diagnos* OR test*); Timespan=All Years (2518)   Database: LILACS <20.04.2015> Search strategy: 1. (tw:(endometriosis)) AND (tw:(diagnos*)) (420)   Database: OAIster (WorldCat.org) <20.04.2015> Search strategy: 1. endometriosis and (marker* or biomarker*) (11) 2. endometriosis and diagnos* (446)   Database: TRIP <20.04.2015> Search strategy: 1. (endometriosis and diagnos*) (1648)    Searches of trial registers for ongoing and registered trials  Database: ClinicalTrials.gov (US NIH) <20.04.2015> Search strategy: 1. endometriosis (220) 2. endometriosis AND diagnosis (22)   Database: WHO International Clinical Trials Registry Platform (ICTRP) <20.04.2015> Search strategy: 1. endometriosis (523)    Searches for the reviews as source of references to potentially relevant studies  Database: MEDION <10.01.2014> (the last available date; database is not updated further) Search strategy: ICP Code female genital system (including breast), Signssymp medical imaging, laboratory tests, histology and cytology, endoscopy and laparoscopy. Filter: systematic reviews of diagnostic studies. (2)    Database: DARE (CRD) <20.04.2015> Search strategy: 1. endometriosis (99)   PubMed, a 'Systematic Review' search under the 'Clinical Queries' link <20.04.2015> Search strategy: 1. (endometriosis) AND systematic(sb) (418) Category: Diagnosis; Scope: Broad   Searches for papers recently published and not yet indexed in the major databases  Search engine: PubMed <20.10.2014 to 20.04.2015> Search strategy:        1. marker (14979) 2. test (61151) 3. diagnos* (69743) 4. biomarker (10806) 5. or/1\u20104 (7943) Filters: Publication date from 2014/10/20 to 2015/04/20   Index test(s) set     6. Endometriosis (584) Filters: Publication date from 2014/10/20 to 2015/04/20   Target condition set     7. 5 and 6 (267) Filters: Publication date from 2014/10/20 to 2015/04/20   Combined sets",
        "Searches for clinical studies": "Database: PsycINFO (Ovid) <1806 to April Week 2 2015 (20.04.2015)> Search strategy: 1. endometriosis.tw. (174)   Database: Web of Science Core Collection (Thomson Reuters) <1900 to Present (20.04.2015)> Search strategy: 1. Topic=(endometrio*) AND Topic=(diagnos* OR test*); Timespan=All Years (2518)   Database: LILACS <20.04.2015> Search strategy: 1. (tw:(endometriosis)) AND (tw:(diagnos*)) (420)   Database: OAIster (WorldCat.org) <20.04.2015> Search strategy: 1. endometriosis and (marker* or biomarker*) (11) 2. endometriosis and diagnos* (446)   Database: TRIP <20.04.2015> Search strategy: 1. (endometriosis and diagnos*) (1648)",
        "Database: PsycINFO (Ovid) <1806 to April Week 2 2015 (20.04.2015)>": "Search strategy: 1. endometriosis.tw. (174)",
        "Database: Web of Science Core Collection (Thomson Reuters) <1900 to Present (20.04.2015)>": "Search strategy: 1. Topic=(endometrio*) AND Topic=(diagnos* OR test*); Timespan=All Years (2518)",
        "Database: LILACS <20.04.2015>": "Search strategy: 1. (tw:(endometriosis)) AND (tw:(diagnos*)) (420)",
        "Database: OAIster (WorldCat.org) <20.04.2015>": "Search strategy: 1. endometriosis and (marker* or biomarker*) (11) 2. endometriosis and diagnos* (446)",
        "Database: TRIP <20.04.2015>": "Search strategy: 1. (endometriosis and diagnos*) (1648)",
        "Searches of trial registers for ongoing and registered trials": "Database: ClinicalTrials.gov (US NIH) <20.04.2015> Search strategy: 1. endometriosis (220) 2. endometriosis AND diagnosis (22)   Database: WHO International Clinical Trials Registry Platform (ICTRP) <20.04.2015> Search strategy: 1. endometriosis (523)",
        "Database: ClinicalTrials.gov (US NIH) <20.04.2015>": "Search strategy: 1. endometriosis (220) 2. endometriosis AND diagnosis (22)",
        "Database: WHO International Clinical Trials Registry Platform (ICTRP) <20.04.2015>": "Search strategy: 1. endometriosis (523)",
        "Searches for the reviews as source of references to potentially relevant studies": "Database: MEDION <10.01.2014> (the last available date; database is not updated further) Search strategy: ICP Code female genital system (including breast), Signssymp medical imaging, laboratory tests, histology and cytology, endoscopy and laparoscopy. Filter: systematic reviews of diagnostic studies. (2)    Database: DARE (CRD) <20.04.2015> Search strategy: 1. endometriosis (99)   PubMed, a 'Systematic Review' search under the 'Clinical Queries' link <20.04.2015> Search strategy: 1. (endometriosis) AND systematic(sb) (418) Category: Diagnosis; Scope: Broad   Searches for papers recently published and not yet indexed in the major databases  Search engine: PubMed <20.10.2014 to 20.04.2015> Search strategy:        1. marker (14979) 2. test (61151) 3. diagnos* (69743) 4. biomarker (10806) 5. or/1\u20104 (7943) Filters: Publication date from 2014/10/20 to 2015/04/20   Index test(s) set     6. Endometriosis (584) Filters: Publication date from 2014/10/20 to 2015/04/20   Target condition set     7. 5 and 6 (267) Filters: Publication date from 2014/10/20 to 2015/04/20   Combined sets",
        "Database: MEDION <10.01.2014> (the last available date; database is not updated further)": "Search strategy: ICP Code female genital system (including breast), Signssymp medical imaging, laboratory tests, histology and cytology, endoscopy and laparoscopy. Filter: systematic reviews of diagnostic studies. (2)",
        "Database: DARE (CRD) <20.04.2015>": "Search strategy: 1. endometriosis (99)",
        "PubMed, a 'Systematic Review' search under the 'Clinical Queries' link <20.04.2015>": "Search strategy: 1. (endometriosis) AND systematic(sb) (418) Category: Diagnosis; Scope: Broad",
        "Searches for papers recently published and not yet indexed in the major databases": "Search engine: PubMed <20.10.2014 to 20.04.2015> Search strategy:        1. marker (14979) 2. test (61151) 3. diagnos* (69743) 4. biomarker (10806) 5. or/1\u20104 (7943) Filters: Publication date from 2014/10/20 to 2015/04/20   Index test(s) set     6. Endometriosis (584) Filters: Publication date from 2014/10/20 to 2015/04/20   Target condition set     7. 5 and 6 (267) Filters: Publication date from 2014/10/20 to 2015/04/20   Combined sets",
        "Search engine: PubMed <20.10.2014 to 20.04.2015>": "Search strategy:        1. marker (14979) 2. test (61151) 3. diagnos* (69743) 4. biomarker (10806) 5. or/1\u20104 (7943) Filters: Publication date from 2014/10/20 to 2015/04/20   Index test(s) set     6. Endometriosis (584) Filters: Publication date from 2014/10/20 to 2015/04/20   Target condition set     7. 5 and 6 (267) Filters: Publication date from 2014/10/20 to 2015/04/20   Combined sets",
        "Appendix 7. Summary of findings table 2 \u2010 Endometrial biomarkers that do not distinguish between women with and without endometriosis": "Review question    Which endometrial biomarkers are unlikely to serve as a basis for a diagnostic test for endometriosis?       Importance    Biomarkers that did not show differential expression in women with and without endometriosis are unlikely to be helpful in a diagnostic sense and hence are not worth pursuing. These findings are based on adequately designed studies that met inclusion criteria for this review.       Patients    Reproductive\u2010aged women with suspected endometriosis or persistent ovarian mass, or women undergoing infertility work\u2010up       Settings    Hospitals (public or private of any level), outpatient clinics (general gynaecology, reproductive medicine, pelvic pain) or radiology departments       Reference standard    Visualisation of endometriosis at surgery (laparoscopy or laparotomy) with or without histological confirmation       Study design    Cross\u2010sectional, single gate design (N = 11) or two\u2010gate design (N = 18); unable to determine if single\u2010 or two\u2010gate design for 2 studies. Prospective enrolment; a study could assess more than 1 test or more than 1 type of endometriosis       Risk of bias     Overall judgement   Poor quality (no studies had 'low risk' assessment in all 4 domains)     Patient selection bias   High risk: 29 studies; unclear risk: 2 studies; low risk: 0 studies     Index test interpretation bias   High risk: 28 studies; unclear risk: 3 studies; low risk: 0 studies     Reference standard interpretation bias   High risk: 0 studies; unclear risk: 13 studies; low risk: 18 studies     Flow and timing selection bias   High risk: 12 studies; unclear risk: 2 studies; low risk: 17 studies      Applicability concerns    Concerns regarding patient selection   High concern \u2010 25 studies; unclear concern \u2010 3 studies; low concern \u2010 3 studies     Concerns regarding index test   High concern \u2010 0 studies; unclear concern \u2010 0 studies; low concern \u2010 31 studies     Concerns regarding reference standard   High concern \u2010 0 studies; unclear concern \u2010 0 studies; low concern \u2010 31 studies      Biomarker     Expression levels     rASRM   stage     Menstrual cycle   phase     Sample   collection method     Reference      1. Angiogenesis and growth factors and their receptors       EGF mRNA (epidermal growth factor)   Endometriosis (N = 35)a: 0.13 \u00b1 0.01  Controls (N = 31): 0.24 \u00b1 0.02; P = 0.120 # sub\u2010analysis per cycle phase \u2010 similar findings   III\u2010IV   Proliferative/secretory   'Endometrial curettage' \u2010 likely sharp   Lee 2007      FGF\u20102 mRNA (fibroblast growth factor\u20102)   Endometriosis (N = 35)a: 17.38 \u00b1 1.73  Controls (N = 31): 20.0 \u00b1 2.53; P = 0.572 # sub\u2010analysis per cycle phase \u2010 similar findings   III\u2010IV   Proliferative/secretory   'Endometrial curettage' \u2010 likely sharp   Lee 2007      Glycodelin mRNA (PP14 or PAEP) (placental protein 14 or progestogen\u2010associated endometrial protein)    Endometriosis (N = 17)a: 2.5 (0.6\u20104.5) Controls (N = 10): 0.936 (0.1\u20101.9); P = NS    II\u2010IV   Proliferative   Sharp curettage   Meola 2009      PDGF\u2010A mRNA (platelet\u2010derived growth factor A)    Endometriosis (N = 35)a: 6.52 \u00b1 0.58  Controls (N = 31): 13.02 \u00b1 1.60; P = 0.572 # sub\u2010analysis per cycle phase \u2010 similar findings   III\u2010IV   Proliferative/secretory   'Endometrial curettage' \u2010 likely sharp   Lee 2007      PIGF (placental growth factor)   Endometriosis (N = 18)a: 120 \u00b1 31  Controls (N = 23): 87 \u00b1 16; P = NS Endometriosis (N = 22)a: 87 \u00b1 30  Controls (N = 27): 109 \u00b1 15; P = NS   III\u2010IV   Proliferative Secretory   Aspiration curettage   Gilabert\u2010Estelles 2007      PIGF mRNA (placental growth factor)   Endometriosis (N = 18)a: 0.050 \u00b1 0.017  Controls (N = 23): 0.032 \u00b1 0.009 Endometriosis (N = 22)a: 0.037 \u00b1 0.016  Controls (N = 27): 0.024 \u00b1 0.004; P = NS   III\u2010IV   Proliferative Secretory   Aspiration curettage   Gilabert\u2010Estelles 2007      PKR1 mRNA (prokineticin receptor 1), EG\u2010VEGF receptor   Endometriosis (N = 9)b: 1.89 (0.1\u20135.5)  Controls (N = 14): 3.92 (0.0\u201323.4); P = NS Endometriosis (N = 6)b: 0.43 (0\u20132.1)  Controls (N = 19): 0.64 (0.0\u20136.7); P = NS   \u2014   Proliferative Secretory   Aspiration curettage   Lee 2010      PKR2 mRNA (prokineticin receptor 2), EG\u2010VEGF receptor   Endometriosis (N = 9)b: 0.93 (0.0\u201310.7)  Controls (N = 14): 0.75 (0.0\u20136.6); P = NS Endometriosis (N = 6)b: 0.24 (0.0\u20131.2)  Controls (N = 19): 0 (0.0\u20131.0); P = NS   \u2014   Proliferative Secretory   Aspiration curettage   Lee 2010      TSP\u20101 (thrombospondin\u20101)   Endometriosis (N = 18)a: 313 \u00b1 46 ng/mg  Controls (N = 23): 210 \u00b1 27 ng/mg; P = NS Endometriosis (N = 22)a: 413 \u00b1 63 ng/mg  Controls (N = 27): 317 \u00b1 42 ng/mg; P = NS   III\u2010IV   Proliferative Secretory   Aspiration curettage   Gilabert\u2010Estelles 2007      TSP\u20101 (thrombospondin\u20101)   Endometriosis (N = 58)a: 140 \u00b1 28 ng/mg  Controls (N = 38): 81 \u00b1 16 ng/mg; P = NS Endometriosis (N = 58)a: 69 \u00b1 16 ng/mg  Controls (N = 38): 69 \u00b1 13 ng/mg; P = NS   \u2014   Proliferative Secretory   Aspiration curettage   Ramon 2011      TSP\u20101 mRNA (thrombospondin\u20101)   Endometriosis (N = 18)a: 2.621 \u00b1 0.735  Controls (N = 23): 1.510 \u00b1 0.270; P = NS Endometriosis (N = 22)a: 3.093 \u00b1 0.7002  Controls (N = 27): 2.370 \u00b1 0.910; P = NS   III\u2010IV   Proliferative Secretory   Aspiration curettage   Gilabert\u2010Estelles 2007      TSP\u20101 mRNA (thrombospondin\u20101)   Endometriosis (N = 58)a: 1.79 \u00b1 0.36  Controls (N = 38): 2.36 \u00b1 0.49; P = NS Endometriosis (N = 58)a: 2.65 \u00b1 0.87  Controls (N = 38): 1.52 \u00b1 0.39; P = NS   \u2014   Proliferative Secretory   Aspiration curettage   Ramon 2011      TYMP (thymidine phosphorylase)   Endometriosis (N = 15)b: 11.8 (2.7\u201338.6) ng/ml  Controls (N = 14): 16.8 (1.1\u201337.6) ng/ml; P = 0.68   III\u2010IV   Proliferative   Aspiration curettage   Laudanski 2014      VEGF (vascular endothelial growth factor)   Endometriosis (N = 10)b: 0.142 (0.087\u20100.943)  Controls (N = 7): 0.129 (0.097\u20100.837); P = 0.943   II\u2010IV   Menstrual   Menstrual fluid   Da Silva 2014      VEGF mRNA (vascular endothelial growth factor)   Endometriosis (N = 24)b: 5.83 (2.5\u20108.75)  Controls (N = 23): 5.01 (1.7\u201010.83); P = NS # sub\u2010analysis per cycle phase \u2010 similar findings   III\u2010IV   Proliferative/secretory   'Endometrial biopsy curette' \u2010 not specified   Cho 2012      EG\u2010VEGF mRNA (endocrine gland\u2010derived VEGF)   Endometriosis (N = 9)b: 0.04 (2.9 \u00d7 10\u20104\u2013 0.6)  Controls (N = 14): 0.03 (5.2 \u00d7 10\u20106\u20131.0); P = NS  Endometriosis (N = 6)b: 0.28 (2.0 \u00d7 10\u20104\u20135.6)  Controls (N = 19): 1.50 (0.0\u201327.9); P = NS   \u2014   Proliferative Secretory   Aspiration curettage   Lee 2010      VEGF/sFlt (VEGF and soluble fms\u2010like tyrosine kinase ratio)   Endometriosis (N = 24)b: 1.06 (0.71\u20102.59)  Controls (N = 23): 0.71 (0.35\u20101.06); P = 0.064 # sub\u2010analysis per cycle phase \u2010 similar findings   III\u2010IV   Proliferative/secretory   'Endometrial biopsy curette' \u2010 not specified   Cho 2012      2. Apoptosis markers and regulators       Bax mRNA (BCL2\u2010associated X protein)   Endometriosis (15)b: 1.22  Controls (N = 30): 1.15; P = NS   I\u2010IV   Proliferative   Sharp curettage   Zubor 2009      Bcl\u2010xL (B\u2010cell lymphoma\u2010extra large, or BCL2\u2010like\u20101 isoform 1)   Endometriosis (15)b: 1.08  Controls (N = 30): 1.07; P = NS   I\u2010IV   Proliferative   Sharp curettage   Zubor 2009      Bcl\u2010xL:Bcl\u2010xS ratio (ratio B\u2010cell lymphoma\u2010extra large/B\u2010cell lymphoma\u2010extra small)E   Endometriosis (15)b: 2.63  Controls (N = 30): 5.63; P = 0.2965   I\u2010IV   Proliferative   Sharp curettage   Zubor 2009      3. Cell adhesion molecules and other matrix\u2010related proteins            \u03b12\u03b21 integrin   Positively stained menstrual effluent: endometriosis (N = 8)c: 7/8  controls (N = 8): 6/8; P = NS Positively stained endometrium: endometriosis (N = 8)c: 8/8  controls (N = 8): 8/8; P = NS   I   Early proliferative (day 2\u20105)   Aspiration curettage   Van der Linden 1994      \u03b13\u03b21 integrin   Positively stained menstrual effluent: endometriosis (N = 8)c: 7/8  controls (N = 8): 6/8; P = NS Positively stained endometrium: endometriosis (N = 8)c: 7/8  controls (N = 8): 7/8; P = NS   I   Early proliferative (day 2\u20105)   Aspiration curettage   Van der Linden 1994      \u03b14\u03b21 integrin   Positively stained menstrual effluent: endometriosis (N = 8)c: 2/8  controls (N = 8): 3/8; P = NS Positively stained endometrium: endometriosis (N = 8)c: 7/8  controls (N = 8): 5/8; P = NS   I   Early proliferative (day 2\u20105)   Aspiration curettage   Van der Linden 1994      \u03b15\u03b21 integrin   Positively stained menstrual effluent: endometriosis (N = 8)c: 7/8  controls (N = 8): 4/8; P = NS Positively stained endometrium: endometriosis (N = 8)c: 8/8  controls (N = 8): 8/8; P = NS   I   Early proliferative (day 2\u20105)   Aspiration curettage   Van der Linden 1994      \u03b16\u03b21 integrin   Positively stained menstrual effluent: endometriosis (N = 8)c: 2/8  controls (N = 8): 3/8; P = NS Positively stained endometrium: endometriosis (N = 8)c: 8/8  controls (N = 8): 8/8; P = NS   I   Early proliferative (day 2\u20105)   Aspiration curettage   Van der Linden 1994      \u03b1V\u03b23 integrin   Positive samples: endometriosis (N = 20)c: 10 (50)  infertile controls (N = 20): 8 (40) fertile controls (N = 20): 7 (35); P = NS endometriosis (N = 16)c: 16 (100)  infertile controls (N = 16): 16 (100) fertile controls (N = 19): 18 (94.7); P = NS   l\u2010II   Mid\u2010secretory Late\u2010secretory   \u2014   Casals 2012      \u03b1V\u03b25 integrins   Glandular cells H Score: endometriosis (N = 40)b: 0.47 (0.0\u20101.0)  controls (N = 12): 0.6 (0.3\u20100.8); P = 0.460 endometriosis (N = 40)b: 1.2 (0.5\u20101.9)  controls (N = 12): 1.3 (0.9\u20101.7); P = 0.507   I\u2010IV   Proliferative Secretory   \u2014   Puy 2002      Stromal cells H Score: endometriosis (N = 40)b: 2.0 (1.0\u20102.7)  controls (N = 12): 1.9 (1.4\u20102.5); P = 0.920 endometriosis (N = 40)b: 1.7 (0.8\u20102.7)  controls (N = 12): 1.5 (1.1\u20102.4); P = 0.752   I\u2010IV   Proliferative Secretory   \u2014   Puy 2002       \u03b1V\u03b26 integrins   Glandular cells H Score : endometriosis (N = 40)b: 0.5 (0.1\u20101.3)  controls (N = 12): 0.75 (0.3\u20101.2); P = 0.856 endometriosis (N = 40)b: 0.7 (0.3\u20100.9)  controls (N = 12): 1.0 (0.8\u20101.2); P = 0.975   I\u2010IV   Proliferative Secretory   \u2014   Puy 2002      Stromal cells H Score: endometriosis (N = 40)b: 1.4 (0.6\u20102.2)  controls (N = 12): 1.2 (0.3\u20102.5); P = 0.651 endometriosis (N = 40)b: 1.8 (0.8\u20102.6)  controls (N = 12): 1.7 (1.0\u20102.2); P = 0.635   I\u2010IV   Proliferative Secretory   \u2014   Puy 2002       ICAM1 (intercellular adhesion molecule1)    Endometriosis (N = 8)a: 0.56 \u00b1 0.25  Control (N = 8): 0.69 \u00b1 0.19; P = NS # sub\u2010analysis per cycle phase \u2010 similar findings   I\u2010IV   Proliferative/secretory   Aspiration curettage   Pino 2009      ICAM1 (CD54) (intercellular adhesion molecule1)    (Small/medium/large cells): endometriosis (N = 10)b:  96 (25\u2013193)/92 (13\u2013106)/106 (18\u2013143) controls (12): 51 (4\u2013453)/48 (5\u2013129)/49 (4\u2013103); P = NS # significant difference between the groups in secretory phase \u2010 no data for 2 \u00d7 2 table    \u2014   Proliferative   Aspiration curettage   Prefumo 2002      sICAM1 (soluble ICAM1)   Endometriosis (N = 8)a: 0.31 \u00b1 0.16  Control (N = 8): 0.13 \u00b1 0.13; P = NS # sub\u2010analysis per cycle phase \u2010 similar findings   I\u2010IV   Proliferative/secretory   Aspiration curettage   Pino 2009      ICAM1 mRNA (intercellular adhesion molecule1)    Endometriosis (N = 6)a: 0.44 \u00b1 0.11  Control (N = 6): 0.76 \u00b1 0.11; P = NS   I\u2010IV   Proliferative/secretory   Aspiration curettage   Pino 2009      E\u2010cadherin   Positively stained menstrual effluent: endometriosis (N = 8)c: 3/8  controls (N = 8): 3/8; P = NS Positively stained endometrium: endometriosis (N = 8)c: 8/8  controls (N = 8): 8/8; P = NS   I   Early proliferative (day 2\u20105)   Aspiration curettage   Van der Linden 1994      LAMA5 (laminin subunit alpha\u20105)   Endometriosis (N = 15)b: 1500 (1060\u20131840) pg/ml  controls (N = 14):1400 (1340\u20131780) pg/ml; P = 0.95   III\u2010IV   Proliferative   Aspiration curettage   Laudanski 2014      LFA\u20103 (CD58) (leukocyte function associated molecule\u20103)   (Small/medium/large cells): endometriosis (N = 10)b:  101 (64 \u2013 302)/108 (28\u2013155)/65 (35\u2013197) controls (12): 315 (65 \u2013 824)/150 (33\u2013264)/124 (67\u2013164); P = NS endometriosis (N = 10)b:  70 (34\u2013252)/49 (26\u2013184)/48 (37\u2013118) controls (12): 171 (145\u2013643)/134 (94\u2013223)/162 (56\u2013228); P = NS   \u2014   Proliferative Secretory   Aspiration curettage   Prefumo 2002      MMP\u20101 (matrix metalloproteinase\u20101)   Endometriosis (N = 8)a: just above detection limit  Control (N = 8): just above detection limit; P = NS   I\u2010IV   Proliferative/secretory   Aspiration curettage   Pino 2009      MMP\u20109 (matrix metalloproteinase\u20109)   Endometriosis (N = 8)a: 2.75 \u00b1 1.5  Control (N = 8): 0.75 \u00b1 0.13; P = NS # sub\u2010analysis per cycle phase \u2010 similar findings   I\u2010IV   Proliferative/secretory   Aspiration curettage   Pino 2009      MMP\u20109 mRNA (matrix metalloproteinase\u20109)   Endometriosis (N = 6)a: 0.21 \u00b1 0.06  Control (N = 6): 0.33 \u00b1 0.07; P = NS   I\u2010IV   Proliferative/secretory   Aspiration curettage   Pino 2009      OPN (osteopontin)   Positive samples: endometriosis (N = 20)c: 14 (70)  infertile controls (N = 20): 13 (65) fertile controls (N = 20): 14 (70); P = NS endometriosis (N = 16)c: 16 (100)  infertile controls (N = 16): 16 (100) fertile controls (N = 19): 19 (100); P = NS   I\u2010II   Mid\u2010secretory Late\u2010secretory   \u2014   Casals 2012      OPN (+)/\u03b1V\u03b23 (+)   Positive samples: endometriosis (N = 20)c: 8 (40)  infertile controls (N = 20): 7 (35) fertile controls (N = 20): 6 (30); P = NS endometriosis (N = 16)c: 16 (100)  infertile controls (N = 16): 16 (100) fertile controls (N = 19): 18 (94.7); P = NS   I\u2010II   Mid\u2010secretory Late\u2010secretory   \u2014   Casals 2012      PAI\u20101 (plasminogen activator inhibitor \u2010 1)   Antigenic levels: endometriosis (N = 21)a: 0.46 \u00b1 0.18 ng/mg  controls (N = 35): 0.73 \u00b1 0.19 ng/mg; P = NS Functional levels: endometriosis (N = 21)a: 1.64 \u00b1 0.59 U/mg  controls (N = 35): 1.12 \u00b1 0.35 U/mg; P = NS   III\u2010IV   Menstrual/proliferative/secretory   \u2014   Gilabert\u2010Estelles 2003      PAI\u20101 (plasminogen activator inhibitor \u2010 1)   Endometriosis (N = 18)a: 1.73 \u00b1 0.56 ng/mg  Controls (N = 23): 1.48 \u00b1 0.40 ng/mg Endometriosis (N = 22)a: 2.51 \u00b1 0.65 ng/mg  Controls (N = 27): 1.44 \u00b1 0.44 ng/mg; P = NS   III\u2010IV   Proliferative Secretory   Aspiration curettage   Gilabert\u2010Estelles 2007      PAI\u20101 mRNA (gene encoding for (plasminogen activator inhibitor \u2010 1)   Endometriosis (N = 18)a: 0.197 \u00b1 0.068  Controls (N = 23): 0.117 \u00b1 0.030 Endometriosis (N = 22)a: 0.496 \u00b1 0.158  Controls (N = 27): 0.131 \u00b1 0.041; P = NS   III\u2010IV   Proliferative Secretory   Aspiration curettage   Gilabert\u2010Estelles 2007      PAI\u20102 (plasminogen activator inhibitor \u2010 2)   Antigenic levels: endometriosis (N = 21)a: 10.69 \u00b1 3.33 ng/mg  controls (N = 35): 4.53 \u00b1 1.75 ng/mg; P = NS   III\u2010IV   Menstrual/proliferative/secretory   \u2014   Gilabert\u2010Estelles 2003      PAI\u20103 (plasminogen activator inhibitor \u2010 3)   Antigenic levels: endometriosis (N = 21)a: 233 \u00b1 50 ng/mg  controls (N = 35): 340 \u00b1 45 ng/mg; P = NS   III\u2010IV   Menstrual/proliferative/secretory   \u2014   Gilabert\u2010Estelles 2003      tPA (tissue\u2010type plasminogen activator)    Antigenic levels: endometriosis (N = 21)a: 12.69 \u00b1 1.52 ng/mg  controls (N = 35): 9.14 \u00b1 1.33 ng/mg; P = NS Functional levels: endometriosis (N = 21)a: 0.41 \u00b1 0.09 U/mg  controls (N = 35): 0.58 \u00b1 0.10 U/mg; P = NS   III\u2010IV   Menstrual/proliferative/secretory   \u2014   Gilabert\u2010Estelles 2003      uPA (urokinase\u2010type plasminogen activator)   Functional levels: endometriosis (N = 21)a: 0.11 \u00b1 0.02 ng/mg  controls (N = 35): 0.06 \u00b1 0.01 ng/mg; P = NS   III\u2010IV   Menstrual/proliferative/secretory   \u2014   Gilabert\u2010Estelles 2003      uPA\u2010R (urokinase\u2010type plasminogen activator receptor)   Antigenic levels: endometriosis (N = 21)a: 2.51 \u00b1 0.55 ng/mg  controls (N = 35): 2.90 \u00b1 0.32 ng/mg; P = NS   III\u2010IV   Menstrual/proliferative/secretory   \u2014   Gilabert\u2010Estelles 2003      tPA\u2010PAI\u20103 (tissue plasminogen activator and plasminogen activator inhibitor \u2010 3 complex)   Antigenic levels: endometriosis (N = 21)a: 0.20 \u00b1 0.10 ng/mg  controls (N = 35): 0.06 \u00b1 0.02 ng/mg; P = NS   III\u2010IV   Menstrual/proliferative/secretory   \u2014   Gilabert\u2010Estelles 2003      uPA\u2010PAI\u20103 (urokinase plasminogen activator and plasminogen activator inhibitor \u2010 3 complex)    Antigenic levels: endometriosis (N = 21)a: 0.27 \u00b1 0.13 ng/mg  controls (N = 35): 0.36 \u00b1 0.18 ng/mg; P = NS   III\u2010IV   Menstrual/proliferative/secretory   \u2014   Gilabert\u2010Estelles 2003      TIMP\u20101 protein (tissue inhibitor of metalloproteinases\u20101)   Endometriosis (N = 45)b: 0.253 \u00b1 0.018  controls (N = 15): 0.267 \u00b1 0.010; P = NS   II\u2010IV   Proliferative/secretory   \u2014   Chen 2004      Endometriosis (N = 21)a: 31\u00b1 6 ng/ml  controls (N = 35): 30 \u00b1 5 ng/ml; P = NS   III\u2010IV   Menstrual/proliferative/secretory   \u2014   Gilabert\u2010Estelles 2003       Endometriosis (N = 15)b: 56.7 (13.5\u2013213.5) ng/ml  Controls (N = 14): 58 (36.2\u2013187.8) ng/ml; P = 0.45   III\u2010IV   Proliferative   Aspiration curettage   Laudanski 2014       TIMP\u20101 mRNA (tissue inhibitor of metalloproteinases\u20101)   Endometriosis (N = 18)a: 1.190 \u00b1 0.228  Controls (N = 23): 1.589 \u00b1 0.335 Endometriosis (N = 22)a: 2.028 \u00b1 0.392  Controls (N = 27): 1.506 \u00b1 0.363; P = NS   III\u2010IV   Proliferative Secretory   Aspiration curettage   Gilabert\u2010Estelles 2007      Endometriosis (N = 35)b: 2.31 \u00b1 1.21  Controls (N = 20): 2.40 \u00b1 0.89; P = NS   I\u2010IV   Proliferative/secretory   'Endometrial curettage' \u2010 not specified   Li 2006       VCAM\u20101 (CD106) (vascular cell adhesion molecule\u20101)   (Small/medium/large cells): endometriosis (N = 10)b:  8 (0\u201342)/3 (2\u201322)/43 (0\u201357) controls (12): 34 (0\u201360)/14 (0\u201324)/21 (0\u201364); P = NS endometriosis (N = 10)b:  28 (5\u201364)/22 (6\u201360)/18 (10\u2013126) controls (12): 27 (5\u2013130)/18 (3\u201362)/33 (13\u2013238); P = NS   \u2014   Proliferative Secretory   Aspiration curettage   Prefumo 2002      4. Cell cycle regulatory molecules       Cyclin B1 mRNA   Endometriosis (N = 20)b: 0.79 \u00b1 1.08  Controls: (N = 30): 0.51 \u00b1 1.04; P = NS Endometriosis (N = 20)b: 0.98 \u00b1 1.24  Controls (N = 30): 0.50 \u00b1 0.49; P = NS # similar findings were observed for protein expression   II\u2010III   Proliferative Secretory   \u2014   Tang 2009      Cdc2 mRNA (cyclin dependent kinase\u20102)   Endometriosis (N = 20)b: 5.0 \u00b1 5.0  Controls: (N = 30): 5.0 \u00b1 5.0; P = NS Endometriosis (N = 20)b: 4.5 \u00b1 5.5  Controls (N = 30): 4.5 \u00b1 5.5; P = NS # similar findings were observed for protein expression   II\u2010III   Proliferative Secretory   \u2014   Tang 2009      Plk1 mRNA (polo\u2010like kinase\u20101)   Endometriosis (N = 20)b: 1.64 \u00b1 1.18  Controls (N = 30): 1.35 \u00b1 0.91; P = NS Endometriosis (N = 20)b: 0.84 \u00b1 1.04  Controls (N = 30): 0.52 \u00b1 0.44; P = NS # similar findings were observed for protein expression   II\u2010III   Proliferative Secretory   \u2014   Tang 2009      5. Cell proliferation markers       Ki\u201067 (Antigen KI\u201067 or MKI67, marker of cellular proliferation)   Stromal cells: endometriosis (N = 13)b: 8.4 \u00b1 1.4  controls (N = 6): 10.9 \u00b1 4.8; P = NS endometriosis (N = 12)b: 9.6 \u00b1 1.8  controls (N = 8): 10.5 \u00b1 4.8; P = NS # data for glandular epithelium and blood vessels are also reported \u2010 no difference between the groups    II\u2010III   Proliferative Secretory   Sharp curettage   Bourlev 2006      BW 495/36, endometrial epithelial marker   Positively stained menstrual effluent: endometriosis (N = 8)c: 8/8  controls (N = 8): 6/8; P = NS Positively stained endometrium: endometriosis (N = 8)c: 8/8  controls (N = 8): 7/8; P = NS   I   Early proliferative (day 2\u20105)   Aspiration curettage   Van der Linden 1995      6. Cytoskeleton molecules       cytokeratin 18   Positively stained menstrual effluent: endometriosis (N = 8)c: 8/8  controls (N = 8): 7/8; P = NS Positively stained endometrium: endometriosis (N = 8)c: 8/8  controls (N = 8): 8/8; P = NS   I   Early proliferative (day 2\u20105)   Aspiration curettage   Van der Linden 1995      CK19 or CYFRA 21\u20101 (cytokeratin 19)   Positively stained menstrual effluent: endometriosis (N = 8)c: 8/8  controls (N = 8): 7/8; P = NS Positively stained endometrium: endometriosis (N = 8)c: 8/8  controls (N = 8): 8/8; P = NS   I   Early proliferative (day 2\u20105)   Aspiration curettage   Van der Linden 1995      Vimentin   Positively stained menstrual effluent: endometriosis (N = 8)c: 8/8  controls (N = 8): 7/8; P = NS Positively stained endometrium: endometriosis (N = 8)c: 8/8  controls (N = 8): 8/8; P = NS   I   Early proliferative (day 2\u20105)   Aspiration curettage   Van der Linden 1995      7. DNA\u2010repair and telomer maintenance molecules       Telomerase activity (relative telomerase activity (RTA))   Endometriosis (N = 30)b: 17.8 \u00b1 30.8  Controls (N = 30): 7.6 \u00b1 13.2; P = NS   I\u2010IV   Proliferative/secretory   \u2014   Kim 2007      8. High throughput markers       mRNAome (mRNA microarray)   Endometriosis (N = 31)d: 0  Controls (N = 18): 0   I\u2010IV   Menstrual/secretory   Aspiration curettage   Fassbender 2012      9. Hormonal markers       EST (oestrogen sulphotransferase)   Glandular cells staining: endometriosis (N = 35)e: strong 2, medium 12, weak 8, absent 25  controls (N = 33): strong 9, medium 8, weak 6, absent 10; P = NS Stromal cells staining: endometriosis (N = 35)e: absent 35  controls (N = 33): absent 33; P = NS   I\u2010II   Proliferative/secretory   'Endometrial curettage' \u2010 likely sharp   Hudelist 2007      LGR7 relaxin receptor mRNA (leucine\u2010rich G protein\u2010coupled receptor 7) evaluated to distinguish endometrioma from other non\u2010malignant ovarian masses   Endometriosis (N = 4)f: 0.95  Controls (N = 7): 1; P = NS Endometriosis (N = 9)f: 1.27  Controls (N = 12): 1; P = NS   III\u2010IV   Proliferative Secretory   \u2014   Morelli 2010      Relaxin mRNA evaluated to distinguish endometrioma from other non\u2010malignant ovarian masses   Endometriosis (N = 13)c: 9 (69.2)  Control (N = 19): 14 (73.7); P = NS # sub\u2010analysis per cycle phase \u2010 similar findings   III\u2010IV   Proliferative/secretory   \u2014   Morelli 2010      10. Immune system and inflammatory markers       A Cytokines      LIF (leukaemia\u2010inhibitory factor)   Endometriosis (N = 14)b: 25.53 (12.63\u201343.32) pg/ml  Controls (N = 21): 36.26 (14.45\u201359.32); P = NS   I\u2010II   Secretory   Uterine flushing   Mikolajczyk 2006      LIF mRNA (leukaemia\u2010inhibitory factor gene)   Endometriosis (N = 14)b: 0.90 (0.73\u20131.09)  Controls (N = 21): 0.92 (0.74\u20131.56); P = NS   I\u2010II   Secretory   Aspiration curettage   Mikolajczyk 2006      TNF\u2010a (tumour necrosis factor\u2010alpha)   Endometriosis (N = 10)b: 386.4 (48.31\u20103636.06)  Controls (N = 7): 56.02 (10.42\u2010619.205); P = 0.219   II\u2010IV   Menstrual   Menstrual fluid   Da Silva 2014      TNF\u2010a mRNA (tumour necrosis factor\u2010alpha)   Endometriosis (N = 25)b: 0.0005 (0.0003\u20130.0020)  Controls (N = 25): 0.0002 (0.0001\u20130.0007); P = NS   I\u2010IV   Proliferative/secretory   'Endometrial curettage' \u2010 not specified   Chen 2013      B Immune cells: peripheral blood mononuclear cells (PBMC)      CD56+ cells (endometrial granulated lymphocytes)   Early/mid/late secretory phase: endometriosis (N = 16)a:  1120 \u00b1 160/1320 \u00b1 160/2200 \u00b1 240 controls (N = 17): 1200 \u00b1 140/1360 \u00b1 200/2440 \u00b1 200; P = NS   I\u2010IV   Secretory   \u2014   Klentzeris 1995      CD38+ cells (endometrial granulated lymphocytes)   Early/mid/late secretory phase: endometriosis (N = 16)a:  950 \u00b1 200/1650 \u00b1 300/3000 \u00b1 300 controls (N = 17): 1550 \u00b1 300/1750 \u00b1 350/3000 \u00b1 250; P = NS   I\u2010IV   Secretory   \u2014   Klentzeris 1995      CD22+ cells (B lymphocytes)   early/mid/late secretory phase: endometriosis (N = 16)a: 87 \u00b1 28/92 \u00b1 31/120 \u00b1 24  controls (N = 17): 90\u00b131/104 \u00b1 39/115 \u00b1 28; P = NS   I\u2010IV   Secretory   \u2014   Klentzeris 1995      CD68+ cells (macrophages)   Endometriosis (N = 31)b: 216.10 \u00b1 104.41  Controls (N = 29): 175.93 \u00b1 43.05; p = 0.06 # sub\u2010analysis per cycle phase \u2010 significant difference between the groups only in proliferative phase \u2010 no data for 2 \u00d7 2 table    I\u2010IV   Any phase   Aspiration curettage   Cetin 2013      CD68+ cells (macrophages)   Early/mid/late secretory phase: endometriosis (N = 16)a:  1178 \u00b1 186/1271 \u00b1 287/1643 \u00b1 248 controls (N = 17): 1054 \u00b1 155/1116 \u00b1 155/1519 \u00b1 287; P = NS   I\u2010IV   Secretory   \u2014   Klentzeris 1995      CD16+ cells (natural killer cells)   Early/mid/late secretory phase: endometriosis (N = 16)a:  1276 \u00b1 377/1305 \u00b1 290/1421 \u00b1 348 controls (N = 17): 957 \u00b1 348/1044 \u00b1 377/1189 \u00b1 290; P = NS   I\u2010IV   Secretory   \u2014   Klentzeris 1995      CD8+ cells (T suppressor/cytotoxic lymphocytes)   Early/mid/late secretory phase: endometriosis (N = 16)a:  691 \u00b1 109/855 \u00b1 127/891 \u00b1 91 controls (N = 17): 782 \u00b1 73/891 \u00b1 91/964 \u00b1 91; P = NS   I\u2010IV   Secretory   \u2014   Klentzeris 1995      CD4+ cells (T helper/inducer lymphocytes)   Early/mid/late secretory phase: endometriosis (N = 16)a:  321 \u00b1 57/357 \u00b1 50/400 \u00b1 64 controls (N = 17): 293 \u00b1 57/307 \u00b1 57/343 \u00b1 57; P = NS   I\u2010IV   Secretory   \u2014   Klentzeris 1995      C Interleukins      IL\u20101\u03b2 mRNA (interleukin \u20101\u03b2)   Endometriosis (N = 25)b: 0.0295 (0.0056\u20130.1039)  Controls (N = 25): 0.008 (0.0040\u20130.0251); P = NS   I\u2010IV   Proliferative/secretory   'Endometrial curettage' \u2010 not specified   Chen 2013      IL\u201011 (interleukin \u2010 11)   Endometriosis (N = 14)b: not detected  Controls (N = 21): not detected; P = NS   I\u2010II   Secretory   Uterine flushing   Mikolajczyk 2006      IL\u201011 mRNA (interleukin \u2010 11)   Endometriosis (N = 14)b: 0.48 (0.39\u20130.59)  Controls (N = 21): 0.52 (0.42\u20130.61); P = NS   I\u2010II   Secretory   Aspiration curettage   Mikolajczyk 2006      IL\u20101R1 mRNA (interleukin \u20101 receptor type II)   Stroma positive samples: endometriosis (N = 17)c: 9 (53)  controls (N = 17): 14 (82); P = 0.299 Glandular cells positive samples: endometriosis (N = 16)c: 13 (81)  controls (N = 17): 14 (82); P = 0.411 # sub\u2010analysis per cycle phase \u2010 similar findings   I\u2010II   Proliferative/secretory   \u2014   Lawson 2008      D other immune/inflammatory markers      MPO (myeloperoxidase)   Endometriosis (N = 10)b: 1.229 (0.778\u20102.094)  Controls (N = 7): 1.69 (0.95\u20101.84); P = 0.669   II\u2010IV   Menstrual   Menstrual fluid   Da Silva 2014      NAG (N\u2010acetyl\u2010\u03b2\u2010D\u2010Glucosaminidase)   Endometriosis (N = 10)b: 723.26 (536.7\u2010768.73)  Controls (N = 7): 663.62 (357.5\u20101214.1); P = 1.0   II\u2010IV   Menstrual   Menstrual fluid   Da Silva 2014      11. Mediators of prostaglandin biosynthesis       Akr1B1 mRNA (aldoketoreductase \u20101B1, PGF2a synthase)   Endometriosis (N = 22)b: 216.9 \u00b1 25.9  Controls (N = 12): 217.6 \u00b1 15.6; P = NS Endometriosis (N = 23)b: 121.2 \u00b1 18.7  Controls (N = 17): 188.3 \u00b1 31.9; P = NS   I\u2010IV   Proliferative Secretory   \u2014   Rakhila 2013      Akr1C3 mRNA (aldoketoreductase \u20101C3, PGF2a synthase)   Endometriosis (N = 22)b: 132.8 \u00b1 21.1  Controls (N = 12): 127.9 \u00b1 26.5; P = NS Endometriosis (N = 23)b: 185.9 \u00b1 31.1  Controls (N = 17): 196.0 \u00b1 45.9; P = NS   I\u2010IV   Proliferative Secretory   \u2014   Rakhila 2013      Cox\u20101 mRNA (cyclo\u2010oxygenase\u20101)   Endometriosis (N = 22)b: 263.6 \u00b1 103.1  Controls (N = 12): 237.9 \u00b1 78.3; P = NS Endometriosis (N = 23)b: 1045.0 \u00b1 313.8  Controls (N = 17): 564.6 \u00b1 151.2; P = NS   I\u2010IV   Proliferative Secretory   \u2014   Rakhila 2013      15\u2010PGDH mRNA (15\u2010hydroxyprostaglandin dehydrogenase)   Endometriosis (N = 22)b: 41.3 \u00b1 11.4  Controls (N = 12): 18.4 \u00b1 3.2; P = NS Endometriosis (N = 23)b: 77.2 \u00b1 51.4  Controls (N = 17): 48.1 \u00b1 26.8; P = NS   I\u2010IV   Proliferative Secretory   \u2014   Rakhila 2013      cPGES mRNA (cytosolic PGE2 synthase)   Endometriosis (N = 22)b: 63.6 \u00b1 4.6  Controls (N = 12): 68.3 \u00b1 4.8; P = NS Endometriosis (N = 23)b: 55.2 \u00b1 4.3  Controls (N = 17): 61.4 \u00b1 3.9; P = NS   I\u2010IV   Proliferative Secretory   \u2014   Rakhila 2013      12. Nerve sheath and nerve growth markers       NF (neurofilament)   Endometriosis (N = 20)b: 0.02 \u00b1 0.10  Controls (N = 20): 0.025 \u00b1 1.04; P = NS   I\u2010II   Secretory   Aspiration curettage   Bokor 2009      NF (neurofilament)   Endometriosis (N = 31): no staining Controls (N = 29): no staining   I\u2010IV   Any phase   Aspiration curettage   Cetin 2013      PGP 9.5 (protein gene product 9.5)   Endometriosis (N = 31): no staining Controls (N = 29): no staining   I\u2010IV   Any phase   Aspiration curettage   Cetin 2013      13. Other peptides and proteins       hBD\u20102 mRNA (human b\u2010defensin\u20102)   Endometriosis (N = 25)b: 0.0343 (0.0025\u20132.0326)  Controls (N = 25): 0.0034 (0.0025\u20130.0424); P = NS   I\u2010IV   Proliferative/secretory   'Endometrial curettage' \u2010 not specified   Chen 2013      hBD\u20102 (human b\u2010defensin\u20102)   Negative samples: endometriosis (N = 25)c: 8 (32)  controls (N = 25): 10 (40); P = NS   I\u2010IV   Proliferative/secretory   'Endometrial curettage' \u2010 not specified   Chen 2013      14. Transcription factors and signalling molecules       AKT1 (RAC\u2010alpha serine/threonine\u2010protein kinase)   Endometriosis (N = 15)b: 7.4 (1.4\u201315.1) ng/ml  Controls (N = 14): 5.6 (1.4\u201315.4) ng/ml; P = 0.9   III\u2010IV   Proliferative   Aspiration curettage   Laudanski 2014      JAG1 (jagged 1 protein)   Endometriosis (N = 15)b: 1.5 (0.3\u20136.5) ng/ml  Controls (N = 14): 1.5 (0.4\u20132.8) ng/ml; P = 0.82   III\u2010IV   Proliferative   Aspiration curettage   Laudanski 2014      NS = Not stated",
        "Appendix 8. Endometrial biomarkers that have limited diagnostic vaue in endometriosis": "Testa      Angiogenesis and growth factors and their receptors      VEGF (vascular endothelial growth factor) protein or mRNA     Cell adhesion molecules and other matrix\u2010related proteins      TIMP\u20101 (tissue inhibitor of metalloproteinases\u20101) protein or mRNA     Hormonal markers      CYP19 (aromatase cytochrome P450)     Notes:a Limited diagnostic value was assigned when there were at least three studies demonstrating low diagnostic estimates that do not meet or approach the criteria for either replacement or triage test, or demonstrating no differential expression in endometriosis. We advise against further evaluation of these biomarkers for the diagnosis of endometriosis.",
        "Appendix 9. Endometrial biomarkers that possibly have limited diagnostic value in endometriosis": "Testa      1. Angiogenesis and growth markers and their receptors      EGF (epidermal growth factor)     FGF\u20102 (fibroblast growth factor\u20102)     glycodelin A (PP14 or PAEP) (placental protein 14 or progestogen\u2010associated endometrial protein)      PDGF (platelet derived growth factor)     PIGF (placental growth factor)     PKR1 (prokineticin receptor 1), EG\u2010VEGF receptor     PKR2 (prokineticin receptor 2), EG\u2010VEGF receptor     PROK\u20101 (prokineticin 1)     TSP\u20101 (thrombospondin\u20101)     TYMP (thymidine phosphorylase)     2. Apoptosis markers and regulators       Bax (BCL2\u2010associated X protein)     Bcl\u2010xL (B\u2010cell lymphoma\u2010extra large, or BCL2\u2010like 1 isoform 1)     Bcl\u2010xL:Bcl\u2010xS ratio (ratio B\u2010cell lymphoma\u2010extra large/B\u2010cell lymphoma\u2010extra small)     3. Cell adhesion molecules and other matrix\u2010related proteins       \u03b12\u03b21 integrin     \u03b13\u03b21 integrin     \u03b14\u03b21 integrin     \u03b15\u03b21 integrin     \u03b16 \u03b21 integrin     \u03b1V\u03b23 integrin     \u03b1V\u03b25 integrins     \u03b1V\u03b26 integrins     \u03b21 integrin     depolarised \u03b16 integrin     ICAM\u20101 (intercellular adhesion molecule\u20101) or sICAM\u20101 (soluble form of intercellular adhesion molecule\u20101)      E\u2010cadherin     LAMA5 (laminin subunit alpha\u20105)     LFA\u20103 (CD58) (leukocyte function associated molecule\u20103)     MMP\u20101 (matrix metalloproteinase\u20101)     MMP\u20109 (matrix metalloproteinase\u20109)     OPN (osteopontin)     PAI\u20101/\u20102/\u20103 (plasminogen activator inhibitors 1/2/3)     PAs: tPA, uPA (plasminogen activators: tissue\u2010type PA, urokinase\u2010type PA)     VCAM\u20101 (CD106) (vascular cell adhesion molecule\u20101)     4. Cell cycle regulatory molecules       cyclin B1     cdc2 (cyclin dependent kinase\u20102)     Plk1 (polo\u2010like kinase\u20101)     5. Cell proliferation markers       Ki\u201067 (antigen KI\u201067 or MKI67, marker of cellular proliferation)     BW 495/36, endometrial epithelial marker     6. Cytoskeleton molecules       cytokeratin 18     CK19 or CYFRA 21\u20101 (cytokeratin 19)     vimentin     7. DNA\u2010repair and telomer maintenance molecules       hTERT (human telomerase reverse transcriptase)     telomerase activity     8. High throughput markers       mitochondrial proteome     mRNAome (mRNA micro\u2010array)     9. Hormonal markers       EST (oestrogen sulphotransferase)     ER \u2010 \u03b1 (oestrogen receptor \u2010 alpha)     ER \u2010 \u03b2 (oestrogen receptor \u2010 beta)     LGR7 (leucine\u2010rich G protein\u2010coupled receptor 7), relaxin receptor     relaxin     10. Immune system and inflammatory markers       Cytokines      LIF (leukaemia\u2010inhibitory factor)     TNF\u2010\u03b1 (tumour necrosis factor alpha)     Immune cells: peripheral blood mononuclear cells (PBMC)      lymphocytes (all, B\u2010, T\u2010cells)     monocytes/ macrophages     NK (natural killer cells)     Interleukins      IL\u20101\u03b2     IL\u201011     IL\u20101R1 (interleukin\u20101 receptor type II)     other Immune/ inflammatory markers      MPO (myeloperoxidase)     NAG (N\u2010acetyl\u2010b\u2010D\u2010Glucosaminidase)     11. Mediators of prostaglandin biosynthesis       Akr1B1 mRNA (aldoketoreductase \u20101B1, PGF2a synthase)     Akr1C3 mRNA (aldoketoreductase \u20101C3, PGF2a synthase)     Cox\u20101 mRNA (cyclo\u2010oxygenase\u20101)     15\u2010PGDH mRNA (15\u2010hydroxyprostaglandin dehydrogenase)     cPGES mRNA (cytosolic PGE2 synthase)     12. Myogenic markers  (markers of smooth muscle differentiation  )      CALD1 (gene encoding for caldesmon)     13. Nerve sheath and nerve growth markers       NF (neurofilament)     14. Other peptides and proteins       hBD\u20102 (human b\u2010defensin\u20102)     15. Transcription factors and signalling molecules       AKT1 (RAC\u2010alpha serine/threonine\u2010protein kinase)     JAG1 (jagged\u20101 protein)     16. Tumour markers       Ca\u2010125 (cancer antigen\u2010125) in menstrual fluid     Notes:a This group comprises the tests that likely to have limited diagnostic value, but where there are insufficient data to confidently comment on their diagnostic role (fewer than three studies with low diagnostic estimates or no differential expression in endometriosis). Further investigation of these biomarkers is possible with a focus on specific phases of the menstrual cycle, specific phenotypes of endometriosis, by implementation of different cut\u2010off values or by utilising different laboratory methods."
    }
}